The development and validation of the visual screening tool for anxiety disorders and depression in people living with hypertension and/or diabetes by Ogle, Zimbini
The development and validation of the Visual Screening Tool for 
Anxiety Disorders and Depression in people living with 
hypertension and/or diabetes 
By 
Zimbini Ogle 
Thesis submitted in fulfilment of the requirements for the degree of 
 Doctor of Philosophy  
Department of Psychiatry  
Faculty of Medicine and Health Sciences 
University of Stellenbosch 
Promotor: Prof Liezl Koen 




By submitting this dissertation electronically, I declare that the entirety of the work contained 
therein is my own and is original work, that I am the sole author thereof (unless to the extent 
explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch 
University will not infringe any third party rights and that I have not previously in its entirety 
or in part submitted it for obtaining any qualification. 
Date: December 2018 
2
Copyright © 2018 Stellenbosch University
All rights reserved
Stellenbosch University  https://scholar.sun.ac.za
ACKNOWLEDGEMENTS 
• Prof Koen, for her patience, contributions and encouragement. Thank you.
• Prof Niehaus, for his support and contributions. Thank you.
• Prof Kidd for assisting with data analysis.
• Jane Metelo-Liquito for the friendship, sisterhood and doing the drawings for the Visual
Screening Tool for Anxiety Disorders and Depression (VISTAD). I love you always.
• Toni and Luke for being family and the rest of their Epstein family for the love,
generosity, kindness and warmth.
• Janine and Roland, for the friendship and support during the data collection.
• The Western Cape Department of Health for granting permission for phase one of the
study.
• The staff at the Maternal Mental Health Clinic at Stikland Hospital for opening the
clinic and supporting the recruitment process.
• Harambee Youth Employment Accelerator for granting permission for part one of the
study.
• The Eastern Cape Department of Health for granting permission to conduct part one
and part two of the study in primary health care centres.
• To the staff members at the clinics who continue to do incredible work; and provided
the space to interview research participants and supporting the recruitment process.
• The individuals who participated in the study; without you the study would not have
been possible.
• My young Wakandas, Siki, Alu and Lukho.
• My mother, Elma “Makhwalo” Ogle, for her patience, love, generosity, strength,
beautiful soul. I pray God keeps you alive to witness.
3
Stellenbosch University  https://scholar.sun.ac.za
• My spiritual father who has always been there, Richard K Kasin and my beloved friend,
Robert Mphiwe. All you have given me is love.
• Thank you Ronald for supporting me. Thank you for the friendship. You are beautiful.
• The beautiful Wakandas who have journeyed with me through challenges, and the
beautiful moments, Babalwa, Jenna, Mandu, Meg, Nosi, Nyameka, Siphokazi, Sizwe,
Weziwe, Lieketseng. Thank you for your love, kindness, patience. You are truly
beautiful to my soul. All I have is love for you and you are all beautiful lovers to me.
4




This study was funded by the Maternal Mental Health Fund, Rural Health Fund, National 
















Stellenbosch University  https://scholar.sun.ac.za
TABLE OF CONTENTS 
 
 Summary……………………………………………………………….7  
 Opsomming…………………………………………………………….11  
 Abbreviations…………………………………………………………..15  
Chapter 1 Introduction and literature review……………………………………….17  
Chapter 2 The development of the visual screening tool for anxiety disorders and 
depression: Addressing barriers to screening for depression and anxiety 
disorders in hypertension and/or diabetes………………………………42 
 
Chapter 3 Depression and anxiety disorders in primary health care patients with 
hypertension and/or diabetes in the Eastern Cape, South Africa……….43 
 
Chapter 4 The validation of the visual screening tool for anxiety disorders and 
depression in hypertension and/or diabetes……………………………..76 
 




Stellenbosch University  https://scholar.sun.ac.za
SUMMARY 
People living with hypertension and/or diabetes have an increased prevalence of depression 
and anxiety disorders. This contributes to functional limitations, poor quality of life, increased 
financial burden and increased suffering. The identification of these mental disorders can 
contribute to addressing the burden imposed by them. However, there are barriers to the 
identification of these disorders, particularly in the South African context. These include a lack 
of tools that can be applied to the diverse South African cultural and language groups and 
people with different levels of education; as well as that a number of screening tools fail to 
meet acceptability for sensitivity in the South African population.  
Attempts to improve availability of screening tools for use at primary health care have included 
the translation of screening tools previously developed in high-income countries. However, 
translated screening tools are often plagued with methodological flaws. In order to address 
some of these limitations, visual screening tools for depression have been developed. These 
tools do not require a patient to be able to read and write, and have been found to be appropriate 
for use in people with low levels of education. They have been shown to be effective in the 
identification of depression in low-income countries. 
In this study, I aimed to develop and validate a visual screening tool for both depression and 
anxiety disorders in people living with hypertension and/or diabetes for use at primary health 
care level. The items for the visual screening tool were based on the Hospital Anxiety and 
Depression Scale (HADS). Compared to similar screening tools, the HADS has been found to 
be an appropriate screening tool for anxiety disorders and depression in people with diabetes, 
and those with low levels of education. However, the HADS is only appropriate for people who 
are able to read and write. 
My study was divided into two phases with each informing the final conclusion. 
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In phase one (reported as one publication), I developed the visual screening tool items by asking 
an artist, Ms Jane Metelo-Liquito, to draw pictures depicting symptoms of depression and 
anxiety disorders. The drawings were based on the HADS. These were shown to a group of 
participants recruited from the general population, primary health care centres and a maternal 
mental health clinic. This was to ascertain the applicability of the drawings across cultures, 
languages and varying levels of education. The findings from phase one of the study indicated 
which drawings were applicable and appropriate for inclusion in the visual screening tool 
named the Visual Screening Tool for Anxiety Disorders and Depression (VISTAD).  
In phase two of the study, I validated the VISTAD. Participants diagnosed with hypertension 
and/or diabetes were recruited from five primary health care centres in the Eastern Cape. This 
province has been identified to have a high prevalence of hypertension and diabetes.  
Using the Mini Neuropsychiatric Interview (M.I.N.I) we demonstrated that 40% of our sample 
had panic disorder, followed by depression (32%), post-traumatic stress disorder (33%), 
generalised anxiety disorder (17%), and then social phobia and agoraphobia (10% for both). 
Current available prevalence rates of depression and anxiety disorders in the hypertension 
and/or diabetes populations are mostly based on research conducted in high-income countries 
and as such my results are a valuable addition for researchers and clinicians. 
Using the WHO quality of life assessment instrument (WHOQOL-BREF) as research tool, I 
found that our participants reported poor quality of life across the domains of physical health, 
psychological health and environment, but not for the social relationships domain. There were 
statistically significant differences in the physical and environment domain of people living 
with hypertension and/or diabetes comorbid with other medical conditions compared to 
participants without other medical conditions. The majority of participants in my study had 
lower levels of education, were unemployed and financial dependent on support from others 
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and our results were largely in keeping with available literature in similar groups. The positive 
association with the social relationships domain could possibly be explained by the fact that 
most participants were reliant on interdependent social structures.  
Only 15% of my sample reported hazardous and harmful alcohol use whilst 17% reported any 
other drug related problems. These are relatively low levels within the South African context 
but are likely explained by the fact that the majority of my participants were female and that 
the sample’s average age was 49.  
The overarching goal of phase two was the validation of the VISTAD (chapter 4) which was 
developed in phase one.  Validation was done against the M.I.N.I and my findings showed that 
the VISTAD has high accuracy in detecting depression and moderate accuracy in detecting 
anxiety disorders in adults with a diagnosis of hypertension and/or diabetes attending primary 
health care centers. The VISTAD is self-administered and any primary health care worker can 
easily be trained to score it. I demonstrated that it can be administered to patients independent 
of level of education, language and cultural background. 
I believe that the VISTAD represents an important contribution towards furthering the 
integration of the management of mental health conditions into the primary health care system.  
Firstly, it addresses the challenges posed by cultural, language, educational and time factors 
when attempting to screen for common mental disorders. Secondly, the VISTAD includes 
symptoms of depression and anxiety disorders in one screening tool. Literature recommends 
that the assessment of depressive disorders should include anxiety disorders since these 
disorders often co-exist in chronic physical conditions. 
It is well known and widely reported in the literature that primary health care access to mental 
health specialists is severely limited. Thus, the true integration of mental health care into 
primary health will improve the early identification and management of depression and anxiety 
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disorders in people living with chronic illnesses. The availability of simple to use and culturally 
appropriate tools such as the VISTAD brings this goal much closer to becoming a reality. 
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OPSOMMING 
Mense wat saamleef met hipertensie en/of diabetes het ‘n hoër prevalensie van depressie en 
angssteurings. Dit dra by tot funksionele inkortings, swak lewenskwaliteit, hoër finansiële las 
en lyding. Identifisering van hierdie psigiatriese siektes kan bydra daartoe om die las wat deur 
hulle veroorsaak word aan te spreek. Daar bestaan egter struikelblokke wat identifisering 
bemoeilik, veral in die Suid Afrikaanse konteks. Dit sluit die gebrek van instrumente wat 
gebruik kan word in die diverse Suid Afrikaanse kulturele- en taalgroepe asook mense met 
verskillende vlakke van opleiding in, sowel as die feit dat baie siftingsinstrumente nie 
aanvaarbare sensitiwiteit toon in die Suid Afrikaanse populasie nie. 
Pogings on die beskikbaarheid van siftingsinstrumente vir gebruik in primêre gesondheidsorg 
te verbeter het ook die vertaling van siftingsinstrumente wat in hoë inkomste lande ontwikkel 
is ingesluit. Vertaalde instrumente toon egter dikwels metodologiese foute. Visuele 
siftingsinstrumente vir depressie is ontwikkel om sommige van hierdie tekortkominge aan te 
spreek. Sulke instrumente benodig nie dat ‘n pasiënt kan lees of skryf nie en is al gewys om 
toepaslik te wees vir gebruik in mense met lae vlakke van opleiding. Hulle is bewys om 
effektief te wees met die identifikasie van depressie in lae inkomste lande.  
My doel met hierdie studie was om ‘n visuele siftingsinstrument vir beide depressie en 
angssteurings te ontwikkel en geldig te bewys in mense met hipertensie en/of diabetes vir 
gebruik op primêre gesondheidsorgvlak. Die items vir die visuele siftingsinstrument was 
gebaseer op die “Hospital Anxiety and Depression Scale (HADS)”. Die HADS is bewys om, 
in vergelyking met soortgelyke instrumente, ‘n toepaslike sfitingsinstrument vir angssteurings 
en depressie te wees in mense met diabetes sowel as diegene met ‘n lae vlak van opleiding. Die 
HADS is egter net toepaslik vir pasiënte wat kan lees en skryf. 
My studie was verdeel in twee fases en elk het die finale gevolgtrekking toegelig. 
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Tydens fase een (gerapporteer as een publikasie) het ek die visuele siftingsinstrument items 
ontwikkel deur ‘n kunstenaar, Me Jane Metelo-Liquito, te vra om sketse te teken wat simptome 
van depressie en angssteurings voorstel. Die sketse was gebaseer op die HADS. Hierdie is 
vertoon aan ‘n groep deelnemers wat gewerf is vanuit die algemene populasie, primêre 
gesondheidsorgsentrums en ‘n moederlike geestesgesondheidskliniek. Dit was om die 
toepaslikheid te bepaal van die sketse regoor die kulturele, taal en opvoedingsvlak spektrum. 
Die bevindinge van fase een van my studie het aangedui watter sketse toepaslik en aanvaarbaar 
was vir insluiting in die visuele siftingsinstrument genoem die “Visual Screening Tool for 
Anxiety Disorders and Depression (VISTAD)”. 
Tydens fase twee van die studie is die geldigheid van die VISTAD bewys. Deelnemers, 
gediagnoseer met hipertensie en/of diabetes, is gewerf vanuit vyf primêre 
gesondheidsorgklinieke in die Oos Kaap. Die provinsie is geidentifiseer om ‘n hoë prevalensie 
van hipertensie en diabetes te hê. 
Deur die “Mini Neuropsychiatric Interview (M.I.N.I)” te gebruik het ons gedemonstreer dat 
40% van ons groep aan panieksteuring ly, gevolg deur post traumatiese stresssteuring (33%), 
depressie (32%), algemene angssteuring (17%) en dan sosiale fobie en agorafobie (beide 10%). 
Huidig beskikbare prevalensiekoerse vir depressie en angssteurings in hipertensie en diabetes 
populasies is hoofsaaklik gebaseer op navorsing uitgevoer in hoë inkomste lande en derhalwe 
is my resultate ‘n waardevolle toevoeging vir navorsers en kliniese personeel. 
Deur die WGO se lewenskwaliteit assesseringsinstrument “(WHOQOL-BREF)” te gebruik het 
ek bevind dat ons deelnemers swak lewenskwaliteit rapporteur oor die domeine van fisiese 
gesondheid, psigiese gesondheid en omgewing, maar nie vir die sosiale verhoudinge domein 
nie. Daar was statisties beduidende verskille tussen die fisiese en omgewings domeine van 
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mense met hipertensie en/of diabetes te same met ander mediese toestande in vergelyking met 
die sonder ander mediese toestande. 
Die meerderheid van die deelnemers in ons studie het laer vlakke van opleiding gehad, was 
werkloos en finansiëel afhanklik van ander en my resultate is dus meerendeels in lyn met 
beskikbare resultate in soortgelyke groepe. Die positiewe assosiasie met die sosiale 
verhoudinge domein kan moontlik verduidelik word deur die feit dat die meeste deelnemers 
deel van was interafhanklike sosiale strukture. 
Slegs 15% van studiegroep het gevaarlike en skadelike alkoholgebruik gerapporteer, terwyl 
17% enige ander dwelm-verwante probleme gerapporteer het. Binne die Suid Afrikaanse 
konteks is hierdie relatiewe lae vlakke wat waarskynlik verklaar kan word deur die feit dat die 
meerderheid van ons deelnemers vroulik was en die gemiddelde ouderdom van die groep 49. 
Die oorkoepelende doel van fase twee was om die VISTAD (hoofstuk vier), wat in fase een 
ontwikkel is, geldig te bewys. Dit is gedoen teen die M.I.N.I. en my bevindinge het gewys dat 
die VISTAD hoë akkuraatheid het om depressie te bespeur en gemiddelde akkuraatheid om 
angssteurings te bespeur in volwassenes met hipertensie en/of diabetes wat primêre 
gesondheidsorgsentra bywoon. Die VISTAD word self beantwoord en enige primêre 
gesondheidsorgwerker kan maklik opgelei word om die totaal te bereken. Ek het demonstreer 
dat die instrument onafhanklik van opleidingsvlak, taal en kulturele agtergrond gebruik kan 
word. 
Ek glo die VISTAD verteenwoordig ‘n belangrike bydrae tot die verbeterde integrasie van die 
hantering van psigiatriese toestande binne die primêre gesondheidsorgsisteem. Eerstens spreek 
dit die uitdagings aan wat kultuur, taal, opleidingsvlak en tydsfaktore bring wanneer ons 
probeer sif vir algemene psigiatriese siektes. Tweedens sluit die VISTAD simptome van beide 
depressie en angssteurings in een visuele siftingsinstrument in. Literatuur beveel aan dat die 
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assessering van depressiewe steurings ook angssteurings moet insluit aangesien hierdie 
steurings dikwels saam voorkom in kroniese fisiese siektes. 
Dit is ook welbekend en word wyd in die literatuur gerapporteer dat die primêre 
gesondheidsorgvlak se toegang tot psigiatriese spesialiskennis ernstig beperk is. Die ware 
integrasie van psigiatriese sorg binne primêre gesondheidsorg sal die vroeë identifikasie en 
hantering van depressie en angssteurings in mense met kroniese siektes verbeter. Die 
beskikbaarheid van kultureel toepaslike instrumente soos die VISTAD wat eenvoudig is om te 
gebruik bring hierdie doelwit veel nader aan ‘n realiteit. 
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CHAPTER ONE 
Introduction and Literature Review 
1.1 Introduction  
The global community, including low- and middle-income countries, is faced with an 
increasing prevalence of non-communicable diseases (Allen 2017; Islam et al., 2014; Mayosi 
et al., 2009; World Health Organization WHO), 2010). These diseases such as diabetes and 
hypertension have been on the rise, with more than one billion individuals suffering world-
wide, according to Khan (2011). They are also highly prevalent in South Africa, with 2.3 
million people living with diabetes (International Diabetes Federation (IDF), 2015), and 30% 
of the South African adult population living with hypertension (Kandala, Tigbe, Manda & 
Stranges, 2013). Both these non-communicable diseases account for 17 million visits annually 
to primary health care (Department of Health, 2013). Singularly, diabetes reduces life 
expectancy by five to ten years (Kumar & Clark, 2017). Hypertension, according to Seedat 
(2015), also reduces life expectancy in men and women, and it is the sixth leading risk factor 
for a life of disability, contributing more than eleven million disability-adjusted life years. In 
South Africa, hypertension is estimated to have caused 46 888 deaths and 390 860 disability-
adjusted lives in the year 2000 (Peltzer & Phaswana-Mafuya, 2013). When co-morbid, 
hypertension and diabetes further reduce life expectancy and increase mortality risk (Safar, 
Gnakaméné, Bahous, Yannoutsos & Thomas, 2017). 
In recent years, researchers have observed co-morbidity between diabetes and hypertension, 
and depression and/or anxiety disorders (Atlantis, Vogelzangs, Cashman & Penninx, 2012; 
Anderson, Freedland, Clouse, & Lustman, 2001; Calvin, Gaviria, & Rios, 2015; Egede et al., 
2016; Lin & Von Korff, 2008; Mendenhall, Norris, Shidhaye & Prabhakaran 2014; Roy & 
Llyod, 2012; Rustad, Musselman & Nemeroff, 2011; Stein et al., 2014; Thomas, Jones, Scarinci 
& Brantley, 2003). One of the early studies was conducted by Rabkin, Charles and Kass (1983) 
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and reported a three-fold higher frequency of major depression in patients treated for 
hypertension. The first report on the relationship between hypertension and emotional stress 
was made by Moschcowitz in 1919. Consistent with early research, current research has shown 
that individuals diagnosed with hypertension have increased prevalence of anxiety disorders 
(Greene, Neria & Gross, 2016). Recent research by Schutte et al. (2015) and Stein et al. (2014) 
has supported Moschcowitz’ association of emotional stress and hypertension by showing that 
anxiety disorders and depression are significantly associated with the subsequent diagnosis of 
hypertension in a South African population. 
Also, the symptoms of depression in people with diabetes are more likely to be severe compared 
to those without diabetes (Hermanns et al., 2013). The association between diabetes and 
depression was first mentioned in 1684 the English physician, Thomas Willis who identified 
emotional factors such as grief and sadness as the cause of diabetes (Geringer, 1990). People 
with diabetes are nearly twice as likely to have depression compared to those without diabetes 
(Roy & Lloyd, 2012). Depression, according to Roy and Lloyd (2012) maybe a consequence 
of diabetes. Roy and Lloyd (2012) base this on biochemical and physiological changes 
associated with diabetes, and also the psychosocial burden imposed by a chronic condition. The 
association between diabetes and depression remains poorly understood (Snoek, Bremmer & 
Hermanns, 2015), with no agreement on the causality and direction of this association. What is 
known from research and clinical practice is that people with diabetes are more likely to have 
depression compared to those without diabetes.  
The co-morbidity with depression and anxiety disorders complicates the burden caused by 
diabetes and hypertension. Moreover, depression and anxiety disorders also contribute to global 
disability (WHO, 2017). Depression and anxiety disorders remain largely undetected and 
untreated at primary health care level. They are often treated at tertiary level institutions as 
opposed to primary health care settings, with Mash (2006) arguing that general practitioners 
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often feel unprepared to deal with common mental disorders. As a result, they may avoid 
dealing with these and feel irritated by patients who present and/or bring up symptoms 
associated with common mental disorders, or refer these patients to a specialist level when they 
could have been managed at a primary health care level (Mash, 2006).  
Because of its accessibility, availability, and continuity of care for the majority of the general 
population in many countries, primary health care is an ideal setting for instituting measures 
that prevent the onset of non-communicable diseases and well as delivering effective 
management where these chronic conditions have been diagnosed (García-Campayo et al., 
2015; Gillam, 2008). Health systems that are oriented towards primary health care are more 
likely to deliver better health outcomes and greater public satisfaction at lower costs, suggests 
Macinko, Starfield, and Shi (2003). However, a major challenge, according to Gillam (2008), 
is the establishment of effective interventions targeting multiple conditions and risk factors 
affecting key groups. These interventions must be appropriately adapted to local 
epidemiological, economic, and sociocultural contexts, adds Gillam (2008). With the increasing 
burden of diabetes, hypertension, depression and anxiety disorders, and the associated co-
morbidity, the integration of mental health services into primary care is recommended.  
1.2 Primary health care 
Ustun and von Korff (1995) define primary health care as the first point of contact where help 
is sought from the medical system and it thus provides continuity of care for common disorders 
and coordination of the delivery of care for different types of health and social services. From 
this description it is clear that primary health care settings are critical for people living with 
chronic illnesses such as hypertension and/or diabetes and thus co-morbid illnesses such as 
depression and/or anxiety disorders should also be managed here. However, these disorders 
remain largely unrecognised and untreated.  
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Researchers have consistently highlighted the shortage of mental health services in the South 
African public health system (Andersen, Kagee, O’Cleirigh, Safren & Joska, 2015). This, 
despite the overwhelming evidence on the burden of these conditions and their cost to society 
when they coexist (Dismuke & Egede, 2011; Egede et al., 2016; Sumlin et al., 2014), as well 
as the Alma Ata Declaration which reaffirmed that health is a state of complete physical, mental 
and social wellbeing, and not merely the absence of disease. While South Africa has adopted 
the underpinning principles of primary health as envisaged in the Alma-Ata declaration, the 
implementation has been mostly of a biomedical orientation. This does not recognise that 
mental disorders which present at primary care owe their origin to a complex array of genetic, 
biological, psychological and social factors (Patel et al., 2016).  
There is increasing evidence suggesting that many clinical problems observed at primary health 
care level are related to mental disorders. Local and international research has demonstrated 
that an increasing number of visits to primary health care are due to mental disorders (Trump 
& Hugo, 2006). Approximately 25–33% of primary health care patients in Ireland present with 
mental health problems (Hughes, Bryne & Synnott, 2010) and more than half (58%) of visits 
to general practitioners in South Africa are due to conditions caused or exacerbated by mental 
disorders (Trump & Hugo, 2006). Although as many as one in four people attending primary 
care providers may be suffering from a mental disorder, less than half are recognised and 
treatment is often inadequate (Mash, 2006).  
1.3 The impact of the co-morbidity between diabetes, hypertension and depression and 
anxiety disorders 
The coexistence of hypertension and/or diabetes with depression and anxiety disorders has been 
shown to have a significant burden including human, social and economic costs. It has a 
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devastating impact on self-care (Sumlin et al., 2014), decreases adherence to treatment 
regimens, decreases quality of life (Goldney, Phillips, Fisher & Wilson, 2004), increases 
mortality risk (Egede & Ellis, 2010) and inflates financial burden associated with health care 
(Dismuke & Egede, 2011; Hutter et al., 2010). The economic impact of common mental 
disorders has been well documented, and the economic costs of depression have been staggering 
world-wide (Rizvi et al., 2015).  
Doherty and Gaughran (2014) report that this co-morbidity often results in complicated 
treatments and poorer outcomes than having either problem alone. That is, either one of the 
physical diseases, or one or both of them, with one, or both, of the mentioned common mental 
disorders. In addition to the negative impact of these conditions, mental disorders in patients 
with chronic physical diseases remain largely undetected and untreated at primary care level 
(Chou, Huang, Goldstein & Grant, 2013; Lotfi, Flyckt, Krakau, Mårtensson & Nilsson, 2010; 
Petersen & Lund, 2011). This leads to prolonged patient suffering and increased risk of greater 
disability (Chou et al., 2013). 
The detection and treatment of depression and anxiety disorders can help address the burden 
imposed by these disorders (Lecrubier, 2001). Jenkins et al. (2013) and Van Oers and 
Schlebusch (2013) identified the lack of appropriate screening tools as one of the barriers in 
detecting mental health problems. Especially multicultural societies such as South Africa with 
its 11 official languages lack screening tools that can be applied to a diverse range of cultural 
and language groups. Language may preclude the marginalised and previously disadvantaged 
groups, and those who do not speak the language of primary health care professionals, from 
receiving the best available care. 
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1.4 Screening and detection of depression and anxiety disorders 
The poor detection of mental disorders in people living with diabetes has been identified as one 
of the biggest challenges in treatment and management (Balhara, 2011). The Behavioural Risk 
Factor Surveillance System conducted in the United States found that up to 45% of the cases of 
mental disorders and severe psychological distress go undetected among patients who receive 
treatment for diabetes (Li et al., 2010). Consequently, the IDF (2015) has recommended 
screening for depression and anxiety disorders in order to improve detection rates and provide 
appropriate care. Patients living with diabetes, according to Li et al. (2010), should be regularly 
screened for common psychiatric disorders. Fisher et al. (2008) suggested screening for distress, 
anxiety and affective disorders several times per year, perhaps at each clinical contact, 
particularly in younger adults and those with complications/co-morbidities. Detection of mental 
disorders is likely to lead to a correct diagnosis where appropriate, and presents the opportunity 
of facilitating appropriate referrals to health professionals (Hermanns et al., 2013).  
Screening has important implications for an individual’s health (Akena, Joska, Obuku & Stein, 
2012), day-to-day clinical practice and public health policy (Hermanns et al., 2013). In 2010, 
the United States identified the need to increase the detection of depression and anxiety 
disorders during routine care at primary health care level. Thus, the importance of enhancing 
the ability of lay workers to provide expert-supervised community based treatment was 
identified. This aimed at addressing the heavy reliance on mental health professionals to assist 
with screening. Gilbody, House, and Sheldon (2005) note the substantial potential for screening 
tools to improve the ability of non-specialists to recognise and manage depression. The 
importance of identifying and managing mental disorders in those with physical health 
problems is well established in literature (McHugh, Brennan, Galligan, McGonagle & Bryne, 
2013). Globally, there has been an increased focus on the integration of mental health into 
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primary health care led by the World Health Organization;  and the South African National 
Department of Health has expressed commitment to the integration of mental health into 
primary care. In order for this to be successful, resources are required, including tools that 
would enable non specialists and lay health care workers working at primary health care to 
identify people living with common mental disorders which are often seen at primary health 
care.  
A number of screening tools have been developed and recommended for use in people with 
diabetes. However, these tools require administration by mental health care specialists, are not 
applicable across cultures, and are not appropriate for people with low levels of education. 
Screening tools such as the Kessler scales have failed to meet acceptability for sensitivity and 
positive predictive value in the South African population (Andersen et al., 2011). 
The accuracy of non-traditional screening tools is likely to address the heavy reliance on mental 
health specialists who are not available and accessible to all mental health care patients. 
Furthermore, these tools can address the language barriers associated with traditional screening 
tools. Alexander, Arnkoff, Kaburu and Glass (2013) previously identified language in screening 
as a contributing factor to the non-detection of mental health problems. Screening tools are 
often translated into other languages for use by other cultural groups. In making screening tools 
available for use across different languages, research evidence has shown that the meaning of 
key concepts are often lost in translation (Kerr & Kerr, 2001). Steele and Edwards (2007) have 
shown that the translation process is often plagued by practical and methodological difficulties 
that threaten the validity of cross-cultural research projects. The translation of concepts across 
cultures is crucial in order to develop culturally appropriate measurement tools, diagnosis, and 
services for people with depression and anxiety disorders (Hermanns et al., 2013).  
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Educational status, according to Foxcroft (2004), is also an important factor to be considered 
when developing a screening tool. Screening tools for depression and anxiety perform poorly 
and are less accurate when screening in people with lower levels of education (Hanlon, Luitel, 
Kathree et al., 2014; Hermanns et al., 2013; Reddy, Philpot, Ford & Dunbar 2010). The 
consideration for level of education is an important factor particularly in the South African 
context. South Africa has been widely reported as country with poor quality of education 
(Branson and Leibbrandt, 2013; Organisation for Economic Co-operation and Development’ 
South Africa’s Policy Brief, 2015). Furthermore, globally, the World Economic Forum ranked 
South Africa’s quality of education amongst the poorest at 137 out of 139 countries (Baller, 
Dutta & Lanvin, 2016).  
In keeping with the focus of primary health care, there is a need to address how mental health 
care services are integrated into primary health care. The integration is not about the insertion 
of a team to manage severe mental disorders on outreach visits by specialists, but rather 
ensuring that primary health care workers are equipped to provide physical and mental care 
simultaneously in one visit. This would also ensure focus on prevention and health promotion.  
1.5 Visual screening tools and analogue scales for depression and anxiety disorders 
Non traditional screening tools for depression and anxiety disorders include visual analogue 
scales which typically use 100mm horizontal line with written descriptors at either side of the 
line, to express the extremes in feeling (Klimek et al., 2017). A visual analogue scale, according 
to Scott and Huskisson (1975) is a straight line with ends showing extreme limits of sensation 
or response to be measured, or the mood in question. Visual analogue scales are available in 
different forms, and these include scales with a middle point, graduations or numbers, meter-
shaped scales analogue scales, box-scales, scales consisting of circles equidistant from each 
other and scales with descriptive terms at intervals along a line (Scott & Huskisson, 1975).  
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These scales were first developed in 1921, and Aitken (1969) was among the first to report on 
their administration assessing depressed mood in participants.  These scales would measure 
people’s feelings, where words fail to fully capture a person’s subjective experience. Aitken 
(1969) argued that people might have an appreciation of how they feel, however, words might 
fail to fully full capture their subjective experience. Since Aitken (1969), a number of visual 
analogue scales have been developed and validated in high income countries (Di Benedetto, 
Kent & Lindner, 2008; Williams, Morlock & Feltner, 2010). Furthermore, visual analogue 
scales are generally used in the assessment of pain (Tamiya et al., 2002; Haefeli & Elfering, 
2006; Hawker, Mian, Kendzerska & French, 2011) and depression in people with stroke 
(Brumfitt & Sheeran, 1999) or acquired brain injury with severe complex disabilities following 
acquired brain injury (Turner-Stokes, Kalmus, Hirani & Clegg, 2005), and assess the severity 
of illness (Ahearn, 1997). 
Amongst the validated analogue scales is the Visual Analogue Mood Scale  (VAMS) developed 
by Stern, Arruda, Hooper, Wolfner and Morey (1997). The VAMS has simple cartoon faces 
which depict a range of “moods”. Each face is placed at the end of a 100 cm line with a neutral 
face placed at the opposite end. Participants are required to indicate where they see themselves 
by placing a mark on the area in question, for example `tired’ versus `neutral’). The VAMS, 
according to Stern et al. (1997) is a reliable measure of internal mood states and can be used 
with people who have impaired language comprehension. The VAMS was specifically created 
for use with post-stroke and other neurologically impaired patients with aphasia and other 
communication disorders using the 100m line with two cartoon faces connecting the line (Stern 
et al., 1997).  
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The General Anxiety - Visual Analogue Scale (GA-VAS) is a 100 mm line shown administered 
as a daily diary format to assess average anxiety over the past 24 hours (Williams et al., 2010). 
The distance from the left edge of the line to the mark placed by the patient is measured to the 
nearest millimeter and used in analyses as the patient GA- VAS score. 
Puertas, Patel and Marshall (2004) developed a visual analogue scale, the FACES test, which 
is a visual representation of mood, consisting of seven graded faces, 1 being happiest mood and 
7 being saddest mood. Puertas et al. (2004)  hypothesized that a visual analogue scale could be 
useful in an environment where literacy was not universal like Western societies. The FACES 
test performed poorly and people with low levels of literacy had difficulties with completing it. 
As a result, this visual analogue scale was not recommended because of its low accuracy. 
Another visual analogue scale is the Distress Thermometer which was developed National 
Comprehensive Cancer Network for measuring distress, even distress unrelated to cancer 
(Holland, 2013). It has a single question which asks patients to place circle a number from 0 to 
10 which best describes how much distress they have been experiencing in the past week 
including today. Patients are further asked to indicate problem areas from a list of 39 items 
where a patient is required to read.  
Some of these visual analogue scales can prove to be problematic.  For example, stroke patients 
may have difficulty in perceiving the spatial relations of the scale and may not be able to 
accurately complete it. Some degree of hemispatial neglect has been proposed in patients living 
with depression and patients experiencing manic symptoms (Ahearn, 1997). Also, the self 
rating screening instruments that the visual analogue scales are often validated against might 
be based on different constructs to the visual analogue scales (Ahearn, 1997). The comparison 
of these two scales, self rating screening tool and visual analogue scale according to Ahearn 
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(1997) may demonstrate good but not exceptional correlation, as these ratings might be 
measuring different aspects of an illness. Berg, Lönnqvist, Palomäki and Kaste (2009) did not 
recommend the Visual Analogue Mood Scale as it had poor sensitivity, 0.20 to 0.60 and did not 
have a correlation with the Beck Depression Inventory in stroke patients. Many validation 
studies for depression screening tools, according to Chorwe-Sungani and Chipps (2017) have 
been conducted in high income countries with a different culture and socio-economic context 
to low resource setting (Chorwe-Sungani & Chipps, 2017). 
Visual analogue scales have not been developed and validated for depression and anxiety 
disorders in people living with hypertension and/or anxiety disorders. Moullec et al. (2010) 
argued that tools cannot be generalized to populations from other cultural or linguistic 
backgrounds different from those who participated in the development of the scales. According 
to Akena (2012) there has been limited work aimed at improving the previous modest 
performances of some visual analogue scales and include a broad range of symptoms of 
depression. Some of the recent improvements of non traditional screening tools have been 
conducted by Akena, Joska, Musisi and Stein (2013) who developed and validated a visual 
screening tool for depression in people living with Human Immunodeficiency Virus and 
Acquired Immune Deficiency Syndrome (HIV/AIDS). Similarly to visual analogue scales, 
visual screening tools are non traditional instruments designed to measure or assess the presence 
of symptoms such as depression. However, screening tools, such as Akena’s use a broad range 
of symptoms based on the Diagnostic Statistical Manual (DSM) criteria to demonstrate 
symptoms of depression using drawings/pictures. Akena et al. (2013) included images depicting 
loss of interest, poor appetite, suicidal ideation, crying spells and low energy. A symptom 
considered to be culturally appropriate was included, namely “worries/too many thoughts” by 
Akena et al. (2013). The aforementioned symptoms were graphically presented to illustrate 
depressive symptoms. These symptoms either had a face or action depicting a normal state or 
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one depicting an abnormal state. A score of 1 was allocated for a normal state and 2 for an 
abnormal state for the following items: sadness, loss of interest, poor appetite, crying spells and 
low energy, and attempted suicide was allocated a score of 3. Akena et al. (2013) found the tool 
to be accurate in screening for depression in people living with HIV/AIDS with low levels of 
education. However, the screening tool developed by Akena et al. (2013) does not screen for 
anxiety disorders. According to Katon, Lin and Kroenke (2007), anxiety disorders should be 
included when screening for depression as these often co-exist in patients living with chronic 
physical conditions. Also, Akena et al. (2013) included a Ugandan culturally appropriate 
symptom for depression.  
With the shift towards integrating mental health care into primary health care, and the 
limitations of current screening tools including, language, education and available visual 
analogue scales, we identify a need to develop and validate a visual screening tool that 
appropriate, accurate across cultures, education levels and language, and does not require to be 
translated into different languages and be used in primary health care settings for people living 
with hypertension and/or diabetes. This would be a tool that is easy and simple to administer 
and score; and accurate in detecting depression and anxiety disorders in people living with 
hypertension and/or anxiety disorders. 
Screening tools must also be acceptable to the person who screens and to the people who are 
screened. With the focus in South Africa on integrating mental health into primary care, simple, 
culture friendly and easy to use tools are required. These should require less intense training 
and inexpensive tools.  
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Central theme and aims of this study 
Visual screening tools for depression and anxiety disorders could possibly circumvent the 
current challenges experienced at primary care settings as posed by cultural, language, 
educational and resource factors. However, available visual screening tools either: (a) neglect 
other symptoms of depression, focussing on sadness as the only symptom, (b) consist of 
matching exercises in which words and definitions are matched but these are most likely only 
available in English, and (c) do not screen for both depression and anxiety symptoms. Screening 
should ideally include both depression and anxiety disorders since these disorders often co-
exist in chronic physical conditions. Our study focused on the development and validation of a 
visual screening tool that could address all of these barriers and the tool is simple and easy to 
administer and score. 
The study was divided into two phases. During phase one, as described in chapter two, we 
focused on investigating the accuracy of pictures in aiding individuals to describe emotions and 
thoughts associated with depression and anxiety disorders in order to develop a culturally 
appropriate and simple visual screening tool that could be applied across language groups and 
levels of education. 
Phase two, as described in chapters three and four focuses on the validation of our newly 
developed tool, the Visual Screening Tool for Anxiety Disorders and Depression (VISTAD). 
For this we chose to recruit a primary care sample of people living with hypertension and/or 
diabetes due to the high prevalence of these illnesses as well as the high known co-morbidity 
with depression and anxiety disorders. In chapter three, the sample recruited is described with 
reference to psychiatric co-morbidity, quality of life and alcohol and drug use. In the last chapter 
of phase two, chapter four, we describe the VISTAD validation process. 
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Research aims and objectives 
The study was conducted in two phases, and the aims of these phases are presented according 
to the three different articles that make up this dissertation. 
Phase one:  
 The development of the Visual Screening Tool for Anxiety Disorders and Depression 
Chapter 2  
Hypertension and diabetes often coexists with depression and/or anxiety disorders. However, 
these disorders are often not detected in people diagnosed with hypertension and/or diabetes. 
The lack of screening tools that can be administered at primary health care level to a diverse 
group of people contributes to the non-detection of these disorders. During phase one we thus 
aimed to develop a visual screening tool for depression and anxiety disorders that could be used 
in a primary health care population diagnosed with hypertension and/or diabetes. For this 
process, the accuracy of the drawings across race, language and different levels of education 
was determined. 
Phase two:  
The validation of the Visual Screening Tool for Anxiety Disorders and Depression and the 
description of the sample recruited for this phase 
Chapter 3  
Previous and current research has shown a high prevalence of depression and anxiety disorders 
in people diagnosed with hypertension and/or diabetes. This co-morbidity has been associated 
with poor quality of life and poor prognosis, increased alcohol and drug use. However, the 
available evidence is often from research conducted in high-income countries and there is little 
information regarding the prevalence of these common mental disorders in patients accessing 
the South African primary health care system. We thus aimed to describe the presence of 
depression, anxiety disorders; and the quality of life  In this chapter we describe the presence 
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of depression and anxiety disorders in the sample recruited for the validation of the visual 
screening tool for depression and anxiety disorders (VISTAD). 
Chapter 4 (Article 3) 
We aimed to validate the visual screening tool for anxiety disorders and depression against the 
Mini-International Neuropsychiatric Interview (M.I.N.I) in adults attending primary care in a 
group of participants living with hypertension and/or diabetes. For this purpose, a language, 
education level and culturally diverse group was recruited in the Eastern Cape Province of 
South Africa. In this chapter we describe the validation process for determining the accuracy 
of the VISTAD in detecting depression and anxiety disorders in these participants. 
31
Stellenbosch University  https://scholar.sun.ac.za
References 
Ahearn, E.P. (1997). The use of visual analogue scales in mood disorders: A critical review. 
Journal of Psychiatric Research, 31(5)569-579. 
Akena, D., Joska, J., Musisi S., & Stein, D.J. (2013). Sensitivity and specificity of a visual 
depression screening instrument among HIV-positive individuals in Uganda, an area 
with low literacy. AIDS and Behaviour, 16(8), 2399–2406.  
Akena, D., Joska J., Obuku, E.A., & Stein D.J. (2012). Sensitivity and specificity of clinician 
administered screening instruments in detecting depression among HIV-positive 
individuals in Uganda. AIDS Care, 25(10), 1245-1252.  
Akena, D. (2012). Screening for depression among HIV-positive patients in a primary health 
care HIV setting in Uganda (Doctoral thesis). University of Cape Town, South Africa. 
Alexander, C.L., Arnko, D.B., Kaburu, A.W., & Glass, C.R. (2013). Detecting depression in 
rural primary care clinics in central Kenya: Impact of a brief training intervention. 
International Perspectives in Psychology Research Practice Consultation, 2(1), 14–28.  
Allen, L. (2017). Are we facing a non communicable disease pandemic? Journal of 
Epidemiology and Global Health, 7(1), 5-9.  
Andersen, L.S, Grimsrud, A., Myer, L., Williams, D.R., Stein, D.J., & Seedat, S. (2011). The 
psychometric properties of the K10 and K6 scales in screening for mood and anxiety 
disorders in the South African stress and health study. International Journal of Methods 
in Psychiatric Research, 20(4), 215–223.  
Andersen, L., Kagee, A., O’Cleirigh, C., & Joska, J. (2015). Understanding the experience and 
manifestation of depression in people living with HIV/AIDS in South Africa. AIDS 
Care, 27(1), 59–62.  
32
Stellenbosch University  https://scholar.sun.ac.za
Atlantis, E., Vogelzangs, N., Cashman, K., & Penninx, B.J.W.H. (2012). Common mental 
disorders associated with 2-year diabetes incidence: The Netherlands Study of 
Depression and Anxiety (NESDA). Journal of Affective Disorders, 142S1, S30–S35. 
Balhara, Y.P.S. (2011). Diabetes and psychiatric disorders. Indian Journal of Endocrinology 
Metabolism, 15(4), 274–283.  
Baller, S., Dutta, S., & Lanvin, B. (2016). The global information technology report 2016: 
Innovating in the digital economy. Available from: 
http://www3.weforum.org/docs/GITR2016/WEF_GITR_Full_Report.pdf 
Branson, N. & Leibbrandt, M. (2013). Education quality and labour market outcomes in South 
Africa”, OECD economics department working papers. No. 1021, OECD Publishing.  
Bos, M., & Agyemang, C. (2013). Prevalence and complications of diabetes mellitus in 
Northern Africa, a systematic review. BMC Public Health, 3(1), 1-7.  
Brumfitt, S.M., & Sheeran, P. (1999). The development and validation of the Visual Analogue 
Self-Esteem Scale (VASES). British Journal of Clinical Psychology, 38, 387-400 
Calvína, J.L.R., Gaviriab, A.Z., & Ríos, M.D.M. (2014).  Prevalence of depression in type 2 
diabetes mellitus. Revista Clinica Espanola, 215, 156-164.  
Chorwe-Sungani, G., & Chipps, J. (2017). A systematic review of screening instruments for 
depression for use in antenatal services in low resource settings. BMC Psychiatry,17, 
112.  
Chou, S. P., Huang, B., Goldstein, R., & Grant, B. F. (2013). Temporal associations between 
physical illnesses and mental disorders--results from the Wave 2 National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Comprehensive 
Psychiatry, 54(6), 627–638.  
33
Stellenbosch University  https://scholar.sun.ac.za
Department of Health Republic of South Africa. (2013) Strategic plan for prevention and 
control of non-communicable diseases 2013-17. 
http://www.hsrc.ac.za/uploads/pageContent/3893/NCDs%20STRAT%20PLAN%20%
20CONTENT%208%20april%20proof.pdf 
Di Benedetto, M., Kent, S., & Lindner, H. (2008). The course of depression 10-weeks post-
acute coronary syndrome: assessment using the cardiac depression visual analogue 
scale. Psychology, Health & Medicine, 00 (0), 1–11. 
Dismuke, C.E., & Egede, L.E. (2011). Association of serious psychological distress 
             with health services expenditures and utilization in a national sample of US adults. 
             General Hospital Psychiatry, 33, 311–317.  
Doherty, A. M., & Gaughran, F. (2014). The interface of physical and mental health. Social 
Psychiatry and Psychiatric Epidemiology, 49(5), 673–682.  
Egede, L.E., & Ellis, C. (2010). Diabetes and depression: Global perspectives. Diabetes 
Research and Clinical Practice, 87, 302 – 312. 
Egede, L. E., Bishu, K. G., Walker, R. J., & Dismuke, C. E. (2016). Impact of diagnosed 
depression on healthcare costs in adults with and without diabetes: United States, 2004-
2011. Journal of Affective Disorders, 195, 119–126.  
Foxcroft, C.D. (2004). Planning a psychological test in the multicultural South African context. 
South African  Journal of Industrial Psychology, 30(4), 8–15.  
García-Campayo, J., Lopez del Hoyo, Y., Valero, M.S., Yus, MCP., Esteban E.A., Guedea, 
MP., & Botaya, R.M. (2015). Primary prevention of anxiety disorders in primary care: 
A systematic review. Preventive Medicine, 76, S12–S15.  
Geringer, E. (1990). Affective disorders and diabetes mellitus. Neuropsychological and  
behavioral aspects of diabetes. New York: Springer. 
34
Stellenbosch University  https://scholar.sun.ac.za
Gilbody, S., House, O., & Sheldon, T. (2005). Screening and case finding instruments for 
depression. Cochrane Database of Systematic Reviews, 4, 1-34.  
Gillam, S. (2008). Is the declaration of Alma Ata still relevant to primary health care? BMJ: 
British Medical Journal, 336(7643), 536–538.  
Goldney, R. D., Phillips, P. J., Fisher, L. J., & Wilson, D. H. (2004). Diabetes, depression, and 
quality of life: A population study. Diabetes Care, 27.  
Greene, T., Neria, Y., & Gross, R. (2016). Prevalence, detection and correlates of PTSD in the 
primary care setting: A systematic review.  J Clin Psychol Med Settings, 23, 160–180.  
Grimsrud, A., Stein, D.J., Seedat, S., Williams, D., & Myer, L. (2009). The association between 
hypertension and depression and anxiety disorders: results from a nationally-
representative sample of South African adults. PLoS One, 4(5), e5552.  
Haefeli, M., & Elfering, A. (2006). Pain assessment. European Spine Journal, 15(1), 17–24.  
Hanlon, C., Luitel, N.P., Kathree, T., et al. (2014) Challenges and opportunities for 
implementing integrated mental health care: A district level situation analysis from five 
low- and middle-income countries. PLoS One, 9(2), e88437.  
Hawker, G. A., Mian, S. , Kendzerska, T. and French, M. (2011), Measures of adult pain: Visual 
Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill 
Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic 
Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure 
of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Research, 63, 
240-252.  
Hermanns, N., Caputo, S., Dzida, G., Khunti, K., Meneghini, L. F., & Snoek, F. (2013). 
Screening, evaluation and management of depression in people with diabetes in primary 
care. Primary Care Diabetes, 7(1), 1–10.  
35
Stellenbosch University  https://scholar.sun.ac.za
Hughes, M., Byrne, M., & Synnott, J. (2010). Prevalence of psychological distress in general 
practitioner adult attendees. Clinical Psychology Forum, 206, 33-38.  
Hutter, N., Schnurr, A., & Baumeister, H. (2010). Healthcare costs in patients with 
diabetes mellitus and comorbid mental disorders--a systematic review. Diabetologia, 
53(12), 2470-9.  
International Diabetes Federation. (2015). IDF Diabetes Atlas 7th ed. Brussels, Belgium: IDF. 
Islam, S. M. S., Purnat, T.D., Phuong, N.T.A., Mwingira, U., Schacht, K., & Fröschl, G.      
           (2014). Non-Communicable Diseases (NCDs) in developing countries: A symposium     
            report. Globalization and Health, 10, 81.  
Jenkins, R., Othieno, C., Okeyo, S., Kaseje, D., Aruwa, J., Oyugi, H., … Kauye, F. (2013). 
Short structured general mental health in service training programme in Kenya improves 
patient health and social outcomes but not detection of mental health problems - a 
pragmatic cluster randomised controlled trial. International Journal of Mental Health 
Systems, 7, 25.  
Kandala, N.B., Tigbe, W., Manda, S.O.M., & Stranges, S. (2013). Geographic variation of 
hypertension in Sub-Saharan Africa: A case study of South Africa. American Journal 
of Hypertension, 26(3), 382-391. 
Kerr, L.K., & Kerr, L.D. (2001). Screening tools for depression in primary care: The effects of 
culture, gender, and somatic symptoms on the detection of depression. Western Journal 
of Medicine,175(5), 349–352.  
Khan, M.G. (2011). Encyclopedia of heart diseases. Volume 1. A-D. second edition. Springer.  
Kumar, P., & Clark, M.L. (2017). Kumar and Clark's Clinical Medicine. 9th Edition. 
Edinburgh: Saunders. 
36
Stellenbosch University  https://scholar.sun.ac.za
Klimek, L., Bergmann, K.C., Biedermann, T., Bousquet, J., Hellings, P., Jung, K., … Pfaar, O. 
(2017). Visual analogue scales (VAS): Measuring instruments for the documentation of 
symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: 
Position Paper of the German Society of Allergology (AeDA) and the German Society 
of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the 
working group on Clinical Immunology, Allergology and Environmental Medicine of 
the German Society of Otorhinolaryngology, Head and Neck Surgery 
(DGHNOKHC). Allergo Journal International, 26(1), 16–24.  
Lecrubier, Y. (2001). The burden of depression and anxiety in general medicine. Journal of 
Clinical Psychiatry, 62(8), 4–9. 
Li, C., Ford, E. S., Zhao, G., Balluz, L. S., Berry, J. T., & Mokdad, A. H. (2010). 
Undertreatment of mental health problems in adults with diagnosed diabetes and serious 
psychological distress: The behavioral risk factor surveillance system, 2007. Diabetes 
Care, 33(5), 1061–1064.  
Lotfi, L., Flyckt, L., Krakau, I., Mårtensson, B., & Nilsson, G.H. (2010). Undetected depression 
in primary healthcare: Occurrence, severity and co-morbidity in a two-stage procedure 
of opportunistic screening. Nordic Journal of Psychiatry, 64(6), 421-427.  
Macinko, J., Starfield, B., & Shi, L. (2003). The contribution of primary care systems to health 
outcomes within Organization for Economic Cooperation and Development (OECD) 
Countries, 1970– 1998. Health Services Research, 38, 831–65.  
Mash, B. (2006). Mental health and primary care. Primary Care. CME, 24(8), 424-425. 
Mayosi, B.M., Flisher, A.J., Lalloo, M.G., Sitas, F., Tollman SM., & Bradshaw D. (2009). 
Health in South Africa 4. The burden of non-communicable diseases in South Africa. 
The Lancet.  
37
Stellenbosch University  https://scholar.sun.ac.za
McHugh, P., Brennan, J., Galligan, N., McGonagle, C., & Byrne, M. (2013). Evaluation of a 
primary care adult mental health service: Year 2. Mental Health in Family Medicine, 
10(1), 53–59. 
Mendenhall, E., Norris, SA., Shidhaye, R., & Prabhakaran, D. (2014). Depression and type 2 
diabetes in low- and middle- income countries: A systematic review. Diabetes Research 
and Clinical Practice, 103, 276–285.  
Moschcowitz, E.L.I. (1919). The American Journal of the Medical Sciences (1827-1924),158 
(5), 668. 
Holland, J. (2013). National Comprehensive Cancer Network Clinical Practice Guidelines in 
Oncology (NCCN Guidelines): Distress management. Version 2.  National 
Comprehensive Cancer Network 
Organisation for Economic Co-operation and Development. (2015) South Africa’s Policy Brief. 
Available from: http://www.oecd.org/southafrica/south-africa-improving-quality-and-
relevance-of-skills.pdf 
Patel, V., Chisholm, D., Parikh, R., Charlson, F. J., Degenhardt, L., Dua, T., …Whiteford, H. 
on behalf of the DCP MNS Author Group  (2016). Addressing the burden of mental, 
neurological, and substance use disorders: key messages from Disease Control Priorities 
(3rd ed.). Lancet, 387, 1672–1685.  
Peltzer, K., & Phaswana-Mafuya, N. (2013). Hypertension and associated factors in older adults 
in South Africa. Cardiovascular Journal of Africa, 24(3), 67–72.  
Petersen, I., & Lund, C. (2011). Mental health service delivery in South Africa from 2000 to 
2010: One step forward, one step back. South African Medical Journal, 101(10), 751-
757.  
38
Stellenbosch University  https://scholar.sun.ac.za
Puertas, G., Patel, V., & Marshall, T. (2004). Are visual measures of mood superior to 
questionnaire measures in non–Western settings? Social Psychiatry and Psychiatric 
Epidemiology, 39(8):662–666.  
Rabkin, J.G., Charles, E., Kass, F., 1983. Hypertension and DSM-III depression in psychiatric 
outpatients. The American Journal of Psychiatry, 140, 1072–1074.  
Reddy, P., Philpot, B., Ford, D., & Dunbar, J.A. (2010). Identification of depression in diabetes: 
The efficacy of the PHQ-9 and the HADS-D. British Journal of General Practice, 
60(575) e239–e245.  
Rizvi, S. J., Cyriac, A., Grima, E., Tan, M., Lin, P., Gallaugher, L. A., … Kennedy, S. H. (2015). 
Depression and employment status in primary and tertiary care settings. Canadian 
Journal of Psychiatry, 60(1), 14–22. 
Roy, T., & Llyod, C.E. (2012). Epidemiology of depression and diabetes: A systematic review. 
Journal of Affective Disorders,142(1), S8–S21.  
Rustad, J,K., Musselman, D,L., & Nemeroff CB. (2011). The relationship of depression and 
diabetes: Pathophysiological and treatment implications. Psychoneuroendocrinology, 
36, 1276—1286.  
Safar, M.E, Gnakaméné, J., Bahous, S.A., Yannoutsos, A., & Thomas, F. (2017). Longitudinal 
study of hypertensive subjects with type 2 diabetes mellitus. Hypertension, 69, 1029-
1035.  
Schutte, A.E., Ware, L.J., Huisman, H.W., Fourie, C.M.T., Greeff, M., Khumalo, T., &  
      Wissing, M.P. (2015). Psychological distress and the development of hypertension over 
     5 years in Black South Africans. The Journal of Clinical Hypertension. 17( 2),  
     126-133.  
Scott, J., & Huskisson, E.C. (1976) Graphic representation of pain. Pain, 2 (2), 175-184. 
39
Stellenbosch University  https://scholar.sun.ac.za
Seedat, Y.K. (2015). Why is control of hypertension in Sub-Saharan Africa poor? 
Cardiovascular Journal of Africa, 6(4), 193-195.  
Snoek, F. J., Bremmer, M. A., & Hermanns, N. (2015). Constructs of depression and distress 
in diabetes: Time for an appraisal. The Lancet Diabetes & Endocrinology, 3(6), 450–
460.  
Steele, G., & Edwards, D. (2007). Development and validation of the Xhosa translations of the 
beck inventories: Challenges of the transla on process. J Psychol Afr, 18(1), 207–216.  
Stein, D. J., Aguilar-Gaxiola, S., Alonso, J., Bruffaerts, R., de Jonge, P., Liu, Z., … Scott, K. 
(2014). Associations between mental disorders and subsequent onset of 
hypertension. General Hospital Psychiatry, 36(2), 142–149.  
Stern, R.A., Arruda, J.E., Hooper, C.R., & Wolfner, G. (1997). Visual analogue mood scales to 
measure internal mood state in neurologically impaired patients: Description and initial 
validity evidence. Aphasiology, 11, 59-71.  
Sumlin, L.L., Garcia, T.J., Brown, S.A., Winter, MA., Garcia, A.A, Brown, A., Cuevas, H.E. 
(2014). Depression and adherence to lifestyle changes in type 2 diabetes: A systematic 
review. The Diabetes Educator, 40(6), 731–44.  
Tamiya, N., Araki, S., Ohi, G., Inagaki, K., Urano, N., Hirano, W., & Daltroy, L. H. (2002). 
Assessment of pain, depression, and anxiety by visual analogue scale in Japanese 
women with rheumatoid arthritis. Scandinavian Journal of Caring Sciences, 16(2), 137-
141. 
Thomas, J., Jones, G., Scarinci I., & Brantley, P. (2003). A descriptive and comparative study 
of the prevalence of depressive and anxiety disorders in low-income adults with type 2 
diabetes and other chronic illnesses. Research. Diabetes Care, 26, 2311–2317. 
Trump, L., & Hugo, C. (2006). The barriers preventing effective treatment of South African 
patients with mental health problems. South African Psychiatry Review, 9, 249-260.  
40
Stellenbosch University  https://scholar.sun.ac.za
Turner-Stokes, L., Kalmus, M., Hirani, D., & Clegg, F. (2005). The Depression Intensity Scale 
Circles (DISCs): A first evaluation of a simple assessment tool for depression in the 
context of brain injury. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1273-
1278. 
Ustun, T.B., & Von Korff, M. (1995). Primary mental health services: Access and provision of 
care. In Ustun., T. B., & Sartorius, N. (Eds.), Mental illness in general health care: An 
international study (pp. 347-360). England. John Wiley and Sons.  
Van Oers, H.M., & Schlebusch, L. (2013). Review article: Anxiety and the patient with breast 
cancer: A review of current research and practice. South African Family Practice, 55(6), 
525–529.  
Williams, V.S.L., Morlock, R.J., & Feltner, D. (2010). Psychometric evaluation of a visual 
analog scale for the assessment of anxiety. Health and Quality of Life Outcomes, 8, 57. 
World Health Organization. (2010). Global status report on non communicable diseases. 
http://www.who.int/nmh/publications/ncd_report_full_en.pdf  
World Health Organization. (2017). depression and other common mental disorders: global  
            health estimates. Available from  
           http://www.hst.org.za/publications/NonHST%20Publications/WHO-MSD-MER-     
2017.2-eng.pdf  
World Health Organization. (1978). Declaration of Alma-Ata. International Conference on 
Primary Health Care, Alma-Ata, USSR, 6-12 September 1978. Available from: 
http://www.who.int/publications/almaata_declaration_en.pd  
41
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER TWO 
This chapter has been published in the African Journal of Primary Health Care & Family Medicine.  
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Diabetes and hypertension are often comorbid with depression and/or anxiety disorders.1,2,3,4,5 
This comorbidity with depression and anxiety disorders has been shown to decrease adherence 
to treatment regimens,6 increase rates of poor quality of life,7 increase mortality risk8 and inflate 
financial burden associated with health care.9,10 In spite of this co-existence and its effects being 
well known, mental disorders in patients with chronic physical illness largely remain undetected 
and untreated at primary health care.11,12,13,14 Lecrubier15 argues that the detection and treatment of 
depression and anxiety disorders can address the burden imposed by these disorders.
Jenkins et al.16 and Van Oers and Schlebusch17 identified the lack of appropriate screening tools as 
one of the barriers in detecting mental health problems. Multicultural societies, such as South 
Africa with its 11 official languages, lack screening tools that can be applied to a diverse range of 
cultural and language groups.18 A number of screening tools fail to meet acceptability for 
sensitivity and positive predictive value in the South African population19 and cannot be 
generalised to populations different from those who participated in their development.20
Screening tools are often translated into other languages for use by other cultural groups. In 
making screening tools available for use in people across different languages, research has 
documented the loss of meaning in translation.21,22 Steele and Edwards23 argue that the translation 
process is often plagued by practical and methodological difficulties that threaten the validity of 
Background: There is a lack of screening tools for common mental disorders that can 
be applied across cultures, languages and levels of education in people with diabetes and 
hypertension.
Aim: To develop a visual screening tool for depression and anxiety disorders that is applicable 
across cultures and levels of education.
Setting: Participants were purposively recruited from two not-for-profit organisations and 
two public health facilities – a maternal mental health unit and a primary health care centre.
Method: This was a qualitative cross-sectional study. Thirteen drawings based on the Hospital 
Anxiety and Depression Scale depicting symptoms of anxiety disorders and depression were 
drawn. Participants described emotions and thoughts depicted in the drawings. Data were 
analysed through content analysis.
Results: Thirty-one women (66%) and 16 men (34%) participated in the development of 
the visual screening tool. The mean age was 34 (standard deviation [SD] 12.46). There were 
32 (68%) black participants, 11 (23%) mixed race participants and 4 (9%) white participants. 
Two participants (4%) had no schooling, 14 (31%) primary schooling, 8 (18%) senior schooling, 
13 (29%) matric qualification and 8 (18%) had post-matric qualification. Participants correctly 
described 10 out of the 13 visual depiction of symptoms as associated with depression and 
anxiety disorders, with no differences between levels of education and cultural groups.
Conclusion: Ten drawings were appropriate for inclusion in the visual screening tool for 
anxiety disorders and depression (VISTAD). The VISTAD will be validated against the mini 
international neuropsychiatric interview (MINI) in a primary care population with hypertension 
and/or diabetes.
The development of the visual screening tool 
for anxiety disorders and depression: Addressing 
barriers to screening for depression and anxiety 
disorders in hypertension and/or diabetes
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the cross-cultural research projects. Hermanns et al.24 argue 
that the translation of concepts across cultures is crucial in 
order to develop culturally appropriate measurement tools, 
diagnoses and services for people with depression and 
anxiety disorders. Language, according to Alexander et al.,25 
is a factor that contributes to the non-detection of mental 
health problems.
Educational status has been highlighted as a critical variable 
to be considered when developing a screening tool.18 
Screening tools for depression and anxiety disorders have 
been found to be less effective in individuals with lower 
levels of education.24,26,27
Researchers have developed screening tools using drawings 
for example, Puertas et al.28 developed the FACES test 
which consisted of schematic faces representing mood 
states ranging from happy to sad face, and from one extreme 
to the other. The FACES test, according to Puertas et al.28 is 
a visual analog scale representation of mood, consisting of 
seven graded faces from happiest mood to saddest mood. 
Puertas et al observed that participants with no education 
were significantly more likely not to be able to answer the 
FACES test.
Contrary to Puertas et al.28 a visual screening tool for depression 
in people living with human immunodeficiency virus (HIV) 
has demonstrated good psychometric properties in people 
with high and low levels of education.29 However, the 
tool neglects anxiety symptoms which often coexist with 
depression. In addition, it focuses on symptoms that often 
overlap with diabetes. Reddy et al.27 argue that symptoms such 
as low energy complicate the diagnosis of depression in people 
with diabetes. They further argue that the hospital anxiety and 
depression scale (HADS) is an appropriate screening tool for 
depression and anxiety disorders in people with diabetes. 
However, tools developed in high-income countries written in 
English for people with higher levels of education might not be 
appropriate for use in a context such as South Africa, especially 
in resource-constrained primary health centres.
The identification of patients with mental health problems 
cannot be successful without culture-fair instruments and 
instruments free of language bias.
Our study aimed to develop a visual screening tool that can 
screen both depression and anxiety disorders in people 
with diabetes and/or hypertension using culture-friendly 
drawings while avoiding some of the limitations associated 
with screening tools.
Methods
Development of the visual screening tool
As a starting point, an artist, Mrs Jane Metelo-Liquito 
(Bachelor of Arts Honors, CDAT-I) was asked to make 
drawings depicting depression and anxiety symptoms 
before the recruitment for the study began. The drawings 
were based on the HADS30 which has been recommended 
for screening for depression and anxiety disorders in 
patients diagnosed with diabetes.27 Figure 1 shows the 
depression and anxiety items included in the development 
of the visual screening tool. Each item consisted of two 
drawings: one drawing depicting an abnormal state and 
the other depicting a normal state. Most of the drawings 
used in the development of the visual screening tool 
focused more on the face. The face, according to Betts,31 is 
predominantly associated with the expression of emotions 
and individual identity.
Setting
The study was conducted in two not-for-profit organisations 
in Cape Town and two public health facilities. The not-for-
profit organisations included a church in a predominantly 
white community and an organisation working with 
business and South African youth in predominantly black 
and mixed-race communities. The two public health facilities 
included a maternal mental health clinic unit and a primary 
health care centre in the Eastern Cape Province of South 
Africa. The multiple settings included in the study serve 
multicultural groups from urban and rural communities 
and this served to minimise bias towards a specific language 
and/or cultural group. South Africa is a diverse country 
with the majority of South Africans being black people 
followed by mixed race people, Indian people, Asian people 
and white people,32 and the most spoken languages are 
iSizulu, isiXhosa, Afrikaans and English out of the 11 official 
languages.
Study design
This was a qualitative cross-sectional study that utilised 
semi-structured interviews to develop depression and anxiety 
disorder items for a new visual screening tool.
Sampling strategy
Purposive sampling was utilised to recruit participants. 
Individuals were recruited while they were at the settings for 
a routine scheduled visit. The purpose of the study was 
explained, and individuals who expressed an interest to take 
part in the study were seen in a private room. The target 
study population excluded people with visual and hearing 
impairment and individuals with intellectual disability based 
on self-report.
Methodologists such as Morse33 recommend 30–60 interviews 
when conducting semi-structured interviews. This is in 
agreement with our initial sample size calculation of 60 (at a 
95% confidence interval and a precision of 12.75). However, 
according to Mason,34 the most common sample sizes are 
between 20 and 30 as the necessary information is easily 
obtained in the interviews and thus fewer participants are 
needed.33 This was also true for our study as themes were 
already established in a sample size of 47 and recruitment 
could be terminated after 3 months.
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Data collection
Data were collected over a period of 3 months through semi-
structured interviews conducted by the principal researcher 
who is a clinical psychologist. The structured interviews 
were conducted in English and Xhosa. English-speaking 
participants were interviewed in English and Xhosa-speaking 
participants were interviewed in Xhosa. The demographic 
questionnaire was administered with all the participants 
after the completion of written informed consent. This 
questionnaire was utilised to collect socio-demographic 
variables such as age, race, sex, marital status, level of 
education, employment status, family income and medical 
conditions. Participants were then asked to describe the 
emotions and thoughts depicted in the 13 drawings, with 
each interview lasting between 20 and 50 min. The responses 
provided by the participants were captured on a spreadsheet 
designed by a statistician.
Data analysis
The data were analysed through content analysis by 
coding the obtained data for words relating to symptoms 
of depression and anxiety disorders. Content analysis begins 
with predefined categories.35 The predefined categories 
(Figure 1) in this study were based on the HADS. Themes 
were identified from the descriptions provided by the 
participants and matched against the HADS items. The 
number of instances in which participants provided 
descriptions in response to emotions and thoughts depicted 
in the drawings was counted.36 The meaning of the themes 
Item Symptoms N % Image
1 Sleep disturbance 38 81
2 Frightened or panic
feeling for no reason
47 100
3 Sad and miserable 46 98
4 Anxious when I go outside
the house on my own
40 85
5 Loss of interest 17 36
6 Palpita!on or sensa!ons
in chest
43 43
7 Loss of appe!te 46 98
8 I feel life is not worth
living
43 91
9 I feel as if I have slowed
down
0 0
Source: Courtesy of artist Jane Metelo-Liquito.
FIGURE 1: The number of participants describing symptoms associated with 
depression and anxiety disorders.





13 Depressed and sad 42 89
10 Restlessness 0 0
Item Symptoms N % Image
Source: Courtesy of artist Jane Metelo-Liquito.
FIGURE 1 (Continues...): The number of participants describing symptoms 
associated with depression and anxiety disorders.
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was interpreted, looking for correlation with the symptoms of 
depression and anxiety disorder as depicted in the drawings.
Trustworthiness of the obtained data was established through 
respondent validation.37 This was done during the interview 
and at the end of the interview where the principal researcher 
restated, questioned and summarised the responses given by 
the participants. This allowed the participants an opportunity 
to affirm or reject the responses.38
Descriptive statistics was used to describe demographic 
data. Demographic data was summarised as frequencies, 
percentages, means with standard deviation (SD). STATA 
version 14 was used for descriptive statistics.
Ethical considerations
Ethical approval was obtained from the Human Research 
Ethics Committee of the Faculty of Medicine and Health 
Sciences at the University of Stellenbosch (Reference number: 
S14/11/262) and permission was obtained from the Western 
Cape Department of Health and the Eastern Cape Department 
of Health to conduct the study. The not-for-profit organisations 
also granted permission to conduct the study.
Results
Forty-seven participants participated in the development of 
the new visual screening tool for anxiety disorders and 
depression (VISTAD). The mean age of the participants was 
34 with SD 12.46 (age range 18–60 years). Thirty-five (74%) 
of the 47 participants were unemployed and 12 (26%) were 
employed. The mean income per month was US $487,70 with 
minimum salary less than US $357,57 and maximum 
US $4290,84 per month. Table 1 provides a descriptive 
overview of the demographics of the study participants.
Our study determined whether participants identified and 
described symptoms associated with depression and anxiety 
disorders correctly. Drawings that depicted symptoms of 
depression were easily identified and described by the 
participants. Items 1, 2, 6 and 7 recorded some of the highest 
frequencies in correct descriptions as symptoms of depression. 
The number of participants (N) who described symptoms of 
depression and anxiety disorders is presented in Figure 1.
As shown in Figure 1, 38 (81%) participants described item 1 
as sleeping disturbance. This description was observed across 
race, gender and different levels of education. The other nine 
participants (19%) described item 1 as depicting sadness and 
depression. Some participants remarked that this is how they 
were when they were stressed, had too much on their minds 
and, as a result, struggled to sleep. Item 3 was described as 
depression, sadness and misery by 46 (98%) participants.
Similar to depression items, anxiety items were described 
correctly as depicting symptoms associated with anxiety 
disorders. For example, item 2 ‘frightened or panic feeling for 
no reason’, was described as anxiety by all the 47 (100%) 
participants providing accurate descriptions.
The participants’ personal narratives were evident in items 
2 and 3. Nine participants (19%) reflected on being diagnosed 
with HIV and associated anxiety symptoms. The participants 
responded in the first person when describing the emotions 
and thoughts depicted in the drawings. Also, it was observed 
that participants became emotional and tearful during the 
interviews. There were 4 participants who became tearful 
during the interviews. In responding to item 3, sad and 
miserable, participants related narrative life stories which 
were characterised by sadness. Item 4, ‘anxious when outside 
on my own’, included ‘scared, hyperalert, fear of being 
attacked, fearful, cannot defend herself, shadow implies fear, 
abused, unsafe’. Participants with varying levels of education, 
different races and languages were able to understand the 
drawings and provided descriptions of symptoms associated 
with anxiety and depression.
Thirty participants (64%) described item 9 as portraying 
sadness and loneliness in a troubled person, and descriptions 
such as the person was praying were also mentioned. Some 
of the participants described the feeling of slowing down as a 
story of a depressed family member (item 9). Furthermore, 
participants empathised with the woman on the drawing 
reporting she was confused, on her own and lived below the 
poverty line (item 9). The feeling of slowing down (item 9) 
and restlessness (item 10) were not identified correctly by all 
the participants. Seven participants (15%) narrated their life 
stories in relation to the feeling of slowing down (item 9) and 
feeling restlessness (item 10). These stories were characterised 
by depression and anxiety. The picture depicting restlessness 
(item 10) was found to be the most unclear item. This was 
described as a group of angry people, poverty-stricken 
individuals, prisoners and sad individuals.






Black people 32 68
Mixed race people 11 23








No schooling 2 4
Primary schooling (Grade 1 and Grade 6) 14 31
Senior schooling (Grade 7 and Grade 11) 8 18
Matric 13 29




N, Number of participants; std dev, standard deviation.
†, There were two missing observations on education variable.
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Participants expressed sadness at the person depicted in 
item 13, stating that the person was stressed and had many 
life problems. Some of the participants personally identified 
with the emotional state depicted in item 13. These 
participants began to describe issues that concerned them in 
life. The descriptions provided by the participants with 
varying levels of education and different races and languages 
were associated with symptoms of depression and anxiety as 
predefined in the HADS, and this showed that the items 
could be considered for inclusion in the visual screening tool.
The items that were frequently described correctly included 
depression items: sleep disturbance, feeling miserable and 
sad, appetite, feeling life is not worth living, and anxiety 
items; feeling frightened or having panic feelings for no 
reason, feeling frightened when going out of the house on my 
own, getting palpitations or sensations ‘butterflies’ in stomach 
or chest, irritable than usual and worrying thoughts. Items 
that were least understood by the participants and did not 
match the predefined categories were removed, both the 
normal and abnormal state drawings.
Discussion
Forty-seven participants participated in the development 
of the VISTAD. The study confirmed that cultural and 
educational background had no bearing on the ability of 
participants to identify and describe symptoms associated 
with depression and anxiety disorders. Participants with low 
levels of education performed similarly to those with higher 
levels of education, and this was observed across cultures. 
Previous studies found visual screening tools to be valid for 
use as screening tools in people with low and high levels of 
education.29 The participants identified symptoms associated 
with depression and anxiety disorders accurately. These 
findings are consistent with observations made by Vick and 
Strauss.39 Also, when providing descriptions, participants 
gave reasons why people felt and thought the way did. 
For example, when the sleep disturbance item was identified, 
participants described reasons why the person on the drawing 
was not sleeping. Furthermore, descriptions of the items 
were connected to personal narratives of the participants. 
Drawings, according to Oster and Crone,40 are often viewed 
as less threatening than direct verbal interaction.
The participants used their life stories in describing emotions 
and thoughts depicted in the drawings. The use of drawings 
potentially offers invaluable opportunities to explore emotional 
status across cultural boundaries. Similar to the Rorschach 
technique, individuals have tremendous freedom of response.41 
Individuals can report on what they are seeing instead of 
offering an either true or false response to a written statement.41 
The use of drawings depicting emotions can provide access 
to the emotions of patients suffering from chronic medical 
conditions. This study lays the groundwork for studying the 
ability of the drawings as a projective tool. The assumption of 
projective instruments is that the respondent will project onto 
an image, thus expressing unconscious needs that he or she is 
ordinarily unable or unwilling to report.42
The participants often responded in the first person and 
added statements such as ‘that was me’ when they identified 
with a specific drawing, such as sleep disturbance item. 
Projective drawings provide information that can enrich 
an individual’s description of his or her own experience.43 
A projective test involves, amongst other stimuli, a drawing 
chosen because it will elicit hidden meanings and not because 
the tester has preconceived ideas of what it should mean.43 In 
our study we held preconceived ideas about what the 
drawings mean as they were based on the HADS. However, 
it was not expected that participants would give personal 
stories in their responses to the drawings. The descriptions of 
the emotions and thoughts were accompanied by narratives 
offering unique material for understanding the participants’ 
life stories.
 The new screening tool was named the VISTAD. Of the 13 
drawings depicting symptoms associated with depression and 
anxiety disorders, we selected 10 to be used in the validation 
study of the VISTAD. These included the normal state 
drawings. Items: ‘feeling as if one’s mind has slowed down’, 
‘restlessness’ and ‘loss of interest’ were excluded from the 
validation study. This included both the drawings portraying 
a normal and an abnormal state. The VISTAD will be validated 
against the mini international neuropsychiatric interview 
(MINI) for accuracy as a screening tool in a primary health care 
population diagnosed with hypertension or diabetes.
Limitations
The research participants were predominantly of a low 
socio-economic status. However, the VISTAD is designed for 
primary health care, and primary health care predominantly 
services people of low socio-economic status. Furthermore, 
the study did not include all racial groups. There were 
no Indian, Asian and Mixed Race participants. The answers 
provided by the participants were captured on a spreadsheet 
during the interview and were not recorded as the participants 
described emotions and thoughts.
Conclusions
The findings of this study demonstrate that the drawings 
are appropriate for use with people from different cultural 
backgrounds and varying educational levels to describe 
the same feelings and thoughts. As a next step, in order 
to establish the psychometric properties of the VISTAD, it 
should be validated against the MINI in a primary health 
care population with hypertension or diabetes.
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CHAPTER THREE 
This chapter presents a description of the presence of depression and anxiety disorders in the 
sample recruited for the validation of the VISTAD. It also describes the quality of life and 
patterns of alcohol and drug use in the study sample living with hypertension and/or diabetes.  
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ABSTRACT 
Background: Hypertension and diabetes have been associated with depression and anxiety 
disorders, poor quality of life and increased alcohol and drug use.  
Aim: This study aimed to assess the number of patients with depression and anxiety disorders 
in a primary care population diagnosed with hypertension and/or diabetes. The study also aimed 
to describe the demographic and comorbid illness characteristics of the sample, including 
patterns of alcohol and drug use. The quality of life was measured and compared with the Visual 
Screening Tool for Anxiety Disorders and Depression (VISTAD) scores. 
Methods: This cross sectional study using purposive sampling was conducted in five primary 
care centers in the Eastern Cape, South Africa. The Mini-International Neuropsychiatric 
Interview was utilized to diagnose depression and anxiety disorders. Fisher’s exact test was 
used to determine the relationship between hypertension and hypertension with diabetes and 
depression and anxiety disorders. The WHOQOL-BREF was used to assess the quality of life. 
We used the Alcohol Use Disorders Identification Test and the Drug Use Disorders 
Identification Test to screen for alcohol and drug use respectively. The VISTAD scores was 
compared with selected illness and quality of life variables. 
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Results: The most common diagnosis was panic disorder (40%), followed by post-traumatic 
stress disorder (33%), depression (32%), generalized anxiety disorder (17%), social phobia 
(10%) and agoraphobia (10%). There was no statistically significant association observed 
between hypertension and/or diabetes and depression (p=.80). There was a statistically 
significant association between hypertension and agoraphobia (p=.04). The quality of life of 
people with hypertension and/or diabetes was found to be poor in all domains except for social 
domain (14.97), physical health (12.42), psychological health (14.17) and environment (12.71). 
There was also a statistically significant associated between depression and poor quality of life 
(p<0.01) across all quality of life domains, physical, psychological, social relationships and 
environment. Participants who endorsed depression and anxiety symptoms reported a poor 
quality of life. Of the sample, 69 (85%) scored between 0–7 on the AUDIT, indicating low risk 
drinking. Five (6%) reported possible dependence, two (3%) hazardous drinking and five (6%) 
harmful levels of drinking. On the DUDIT, 65 (83%) reported no drug related problems, 1 (1%) 
drug dependence and 13 (16%) drug related problems. 
Conclusion: Depression was significantly associated with poor quality of life on physical, 
psychological, social relationships and environment domains whereas anxiety disorder had a 
statistically significant association with some of the quality of life domains. The study 
underscores the importance of detecting depression and anxiety disorders in people with 
hypertension and/or diabetes. 
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INTRODUCTION 
The burden of disease, including non communicable disease has increased globally. The global 
burden of mental, neurological and substance-use disorders increased by 41% between the year 
1990 and 2010.1 Hypertension and diabetes have emerged as major contributors to the world-
wide burden of disease. According to the International Diabetes Federation Atlas (IDF),2 there 
are approximately 450 million people world-wide living with diabetes. Similarly to the high 
prevalence of diabetes, over 1.3 billion people are living with hypertension.3 Both hypertension 
and diabetes are highly prevalent in South Africa with 2.3 million people living with diabetes,2 
and 6.3 million with hypertension.4 Individuals living with hypertension and diabetes have a 
higher prevalence of depression and anxiety disorders compared to those without these 
illnesses.5 Alkhathami, Alamin, Alqahtani, Alsaeed, Alkhathami and Al-Dhafeeri (2017)6 
found a prevalence of 48.7% for depression and 38.4% anxiety in people living with 
hypertension and/or diabetes attending primary health care. Teixeira et al. (2015)7 reported 
depression (severe) 35% and anxiety (severe) 26% in sample of 34 participants with 
hypertension and/or diabetes. In a sample of participants living with diabetes, Goldney, Phillips, 
Fisher, and Wilson8 reported a prevalence of 24% for depression South Australia. Researchers 
in India reported a prevalence of 62% for depression and 49% for anxiety in people living with 
Type 2 diabetes.9 There is less research reporting on the association between hypertension and 
depression10 and association between depression and anxiety disorders in both hypertension 
and/or diabetes compared to depression and diabetes only. 
Investigating the comorbidity between hypertension and/or diabetes and depression and anxiety 
disorders is crucial as this comorbidity has been associated with adverse consequences. These 
include poor adherence to treatment regimens and poor self-care behaviors.5,8 Also, 
hypertension and diabetes often coexist11,12 and both hypertension13,14 and diabetes11, have been 
associated with a poor quality of life (QOL). Quality of life, according to Rubin and Peyrot 
(1999)11 is an important health outcome for all health interventions and has also been 
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specifically shown to act as important indicator in the evaluation of hypertension treatment 
outcomes.15 Quality of life can also serve as an important outcome measure for pharmacological 
or non-pharmacological interventions.16 With the increase in hypertension and diabetes 
prevalence and the recorded negative medical impact on the lives of individuals, it is critical to 
understand the QOL of individuals diagnosed with these illnesses.  
 
In addition to the association between hypertension and diabetes and QOL, previous research 
has demonstrated an association between hypertension, diabetes, mental disorders, alcohol and 
drug use.17-19 The association between alcohol use and depression20 and anxiety disorders21 has 
consistently been reported. Collectively, these disorders, combined with hypertension and 
diabetes, contribute to a substantial burden of disease.22-24 
 
Overall, the coexistence of hypertension and/or diabetes with depression and/or anxiety 
disorders presents a burden on health care resources. In addition to the negative impact, these 
conditions increase the mortality risk,9 and inflate the financial burden associated with health 
care.25,26 Studies have investigated the number of people living with depression and anxiety 
disorders who suffer from hypertension and/or diabetes. However, these studies have mostly 
been conducted in developed countries.27,28 Furthermore, many of these studies have 
specifically focused on diabetes and depression excluding hypertension and anxiety disorders, 
with few studies investigating the association between depression (and anxiety disorders) and 
hypertension.28,29  
 
The lack of research investigating depression and anxiety disorders in people living with 
hypertension and/or diabetes limits our ability to better understand and manage the implications 
of this burden. Especially, the dearth of locally conducted studies hinders our ability to allocate 
necessary resources and develop interventions for people living with diabetes and/or 
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hypertension comorbid with depression and anxiety disorders. Data from South Africa are 
needed in order to develop a full understanding of the prevalence of depression and anxiety 
disorders and for planning the provision of integrated mental health care for people living with 
hypertension and/or diabetes. We aimed to describe the presence of depression and anxiety 
disorders in a sample that was used to validate the Visual Screening Tool for Anxiety Disorders 
and Depression (VISTAD),30 and to investigate the association between quality of life and 
hypertension and/or diabetes and depression and anxiety disorders. We also aimed to describe 





This cross sectional study using purposive sampling was conducted in five primary health care 
centers (two urban, one peri-urban, and two rural) in the Eastern Cape, South Africa. 
Participants diagnosed with hypertension and/or diabetes were recruited from these centres. 
This province has been identified to have a high prevalence of hypertension and diabetes.31,32 
Participants who potentially met the study criteria were either referred by primary health care 
workers or recruited by the researcher through purposive sampling. Thirty-one (38%) 
participants were from clinics in urban centers, 39 (48%) from rural and 11 (14%) from peri-
urban centers in the Eastern Cape. Eighteen participants were Mixed Race, 13 White and 50 
Black. The specific primary health care centres used as study sites were identified based on 
their accessibility and reduced interference due to service delivery protests that were ongoing 
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Study population 
Eighty-one participants diagnosed with hypertension and/or diabetes were recruited. Since 
hypertension and diabetes are frequently comorbid conditions, we recruited participants with 
either hypertension or diabetes or with both of these conditions. Purposive sampling which 
refers to the selection of a sample that the researcher perceives to be a “typical” sample based 
on selection criteria was utilized for this study. Primary health care staff at the study settings 
were requested to inform patients who had hypertension and/or diabetes and possibly met the 
inclusion criteria about the study, and then refer those who expressed an interest. The researcher 
also spoke to patients in the waiting area at the study setting and those who self-reported a 
diagnosis of hypertension and/or diabetes were informed of the study. Recruitment was done 
on the “chronic days”. “Chronic days” are days scheduled for treatment of people living with 
chronic medical conditions such as diabetes and hypertension, but excluding Human 
Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (HIV/AIDS). This 
allowed the researcher to easily identify possible participants. Participants who expressed an 
interest were invited to a separate room to meet with the researcher. Those who met criteria, 
were willing to participate and had capacity to consent were included. Individuals with 
intellectual disability, or visual and/or hearing impairment were excluded.  
 
Questionnaires 
A demographic questionnaire was used to collect data such as age, race, gender, marital status, 
level of education, employment status, family income, dwelling type, number of people in 
household, history of mental illness, other medical conditions and disability. Depression and 
anxiety disorders were assessed according to Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) criteria set out on the MINI International Neuropsychiatric 
Interview (M.I.N.I) version 5.0.33 The M.I.N.I has been widely used as a diagnostic tool in 
people with diabetes only,34,35 and diabetes and hypertension.36 Whilst the M.I.N.I has not 
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specifically been validated for use at primary health in people living with diabetes and/or 
hypertension, it has been widely used in South Africa and found to be a valid and reliable tool.37 
The M.I.N.I has very good operating characteristic.38 It is characterized by good and very good 
kappa values and higher specificities and negative predictive values of 0.85 or higher across all 
the diagnosis. Positive predictive values (PPV) for depression, panic disorder, post traumatic 
stress disorder are above 0.75 indicating very good (PPV). The M.I.N.I has been described as 
a gold standard in the validation of screening tools in the African context. Also, the M.I.N.I was 
used as a gold standard in the validation of a visual screening tool for depression39 which is 
similar to the VISTAD.30 Validation studies have reported AUC of ranging from	0.7737 to 0.8239 
and 0.77 for post traumatic stress disorder, and 0.78 for generalized anxiety disorder.37  
 
The WHO quality of life assessment instrument (WHOQOL-BREF), which was developed 
cross culturally by the WHO as a self-report questionnaire, was used to assess the QOL. This 
tool comprises 26 items with four different facets or domains of QOL, namely physical health 
(DOM 1), psychological health (DOM 2), social relations (DOM 3) and environment (DOM 
4).40 Each domain is scored, and then scores are transformed according to the WHOQOL-BREF 
manual.41 Higher scores denote a higher QOL. The WHOQOL-BREF has not been validated 
for use in South African primary care patients living with hypertension and/or diabetes. 
However, the WHOQOL-BREF has shown good consistency and reliability in diverse groups 
and centers.42 
 
 The VISTAD30 was developed as a screening tool for depression and anxiety disorders in a 
primary care population living with hypertension and/or anxiety disorders. The VISTAD has 
10 items which screen for depression and anxiety disorders in people living with hypertension 
and/or diabetes. A score of 1 is allocated when a participant endorses an abnormal state drawing 
and 0 when none of the abnormal state symptoms are endorsed. The maximum score that could 
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be obtained on the VISTAD is 10. A score of 6 or more on the VISTAD indicates a positive 
screen for depression and anxiety disorders. 
 
Statistical analyses 
Descriptive statistics were used to describe the study sample and the prevalence of depression 
and anxiety disorders. Fisher’s exact test was used to determine the relationship between 
hypertension and diabetes and depression and anxiety disorders. An analysis for the diabetes 
only group was not conducted as there was only one participant who fell in this group. The 
participant was not removed in the overall data analysis as our study sample was relatively 
small. We compared hypertension only with hypertension comorbid with diabetes to determine 
if a comorbid diagnosis was associated with being diagnosed with depression and anxiety 
disorders. Cronbach’s alpha was used to estimate the reliability of the WHOQOL-BREF. 
Cronbach’s alpha values of 0.80 and above were regarded to be acceptable.40 We used the 
Mann-Whitney U Test to compare mean scores between people with and without medical 
conditions (HIV and diabetes were also analyzed as separate variables given the prevalence in 
the sample and clinical features of these disorders). The level of significance was set at p < 0.05 
for all analyses which were performed using STATA, version 14. 
 
Ethical considerations 
Ethical considerations were the same as those in the main/parent study as this was one study 
with different aims and aspects. Ethical approval was granted by the University of Stellenbosch 
Faculty of Medicine and Health Sciences Human Research Ethics Committee (Reference 
number: S14/11/262) (Addendum 1). Permission to conduct the study was obtained from the 
Eastern Cape Department of Health, South Africa. The study was conducted according to the 
ethical guidelines and principles of the International Declaration of Helsinki, South African 
Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
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Guidelines for Research. 
 
RESULTS 
Eight-one participants were recruited and interviewed, but only 79 participants completed the 
demographic questionnaire and thus represent the sample described in Table 1. Two 
participants had incomplete demographic data and their data was used in the analysis of 
WHOBREF-QOL. The mean age of the participants was 49 years, with standard deviation 8.7 
and a range of 22–60 years. The majority of the participants interviewed were female 69 (87%). 
Most of the participants were Black 50 (63%), 16 (20%) Mixed Race, and 13 (17%) White. The 
majority were unemployed 58 (73%) with the minimum monthly income $15,12 and the median 
$143,39. The highest monthly income was $3018,80. Forty-seven of the participants had a 
diagnosis of hypertension (59%), followed by hypertension co-morbid with diabetes in 31 
participants (39%) and a single participant with diabetes only. The total of 81 participants were 
recruited from clinics in Port Elizabeth, 23 from Algoa Park Clinic and 8 from kwaMagxaki 
Clinic. Eleven participants were recruited from Uitenhage clinic; 19 from Wentzel Park Clinic 
and 20 from kwaNonkqubela Clinic, the last two sites being in Alexandria. 
Table 1: Demographic characteristics of participants (N=79) 
Variable  N % 
Gender   
Female 69 87 
Male 10 13 
Education   
No education 2 3 
Primary level (grade 1 to grade 6) 25 32 
Senior level (grade 7 to grade 11) 33 42 
Matric 15 19 
Post-Matric qualification 4 5 
Employment   
Yes 21 27 
No 58 73 
Chronic Illness   
Hypertension only 47 59 
Hypertension and diabetes 31 39 
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Diabetes  1 1 
N, Number of participants who completed the demographic questionnaire 
 
Forty-three (54%) of the participants reported that they had other existing medical conditions 
including HIV/AIDS (25%), asthma (28%), arthritis (25%), and high cholesterol (21%). Only 
ten (13%) participants reported they had previously been informed that they suffered from a 
mental disorder.  
 
Substance and alcohol patterns in the sample 
In our study sample (85%) scored between 0–7 on the AUDIT, indicating low risk drinking, 
3association between the VISTAD and a positive AUDIT score. However, participants who 
screened positively with drug related problems on the DUDIT endorsed the suicide item more 
often (42% versus 15.6%, Chi sq .033) and irritability (64% versus 28%, Chi sq .014). 
 
Major Depressive and Anxiety Disorders in the sample 
Panic disorder was the most commonly diagnosed mental disorder during our study, followed 
by post-traumatic stress disorder (PTSD), depression, generalized anxiety disorder (GAD), 
social phobia and agoraphobia, as shown in Table 2. 








Hypertension & diabetes  p-value 
Depression 24 (33) 14 (30%) 10 (33%) 0.80 
Panic disorder 32 (40) 18 (38%) 11 (37%) 1.00 
PTSD 27 (33) 14 (30%) 11 (37%) 0.62 
Social phobia 8 (10) 6 (13%) 2 (7%) 0.47 
Agoraphobia 8 (10 7 (15%) 0 (0.00%) 0.03* 
GAD 14 (17) 7 (15%) 6 (20%) 0.75 
*indicates statistically-significant Fisher exact test 
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Seventeen percent of the total sample of 81 had been diagnosed with one mental disorder, whilst 
25% of the total sample had 2 comorbid mental disorders, 11% had 3 comorbid mental 
disorders. There were 6 (7%) of the total sample with 4 comorbid mental disorders and only 2 
(2%) with 5 comorbid mental disorders. Agoraphobia was likely to coexist with panic disorders 
with Cohen’s kappa of 0.29. Depression and generalized anxiety were likely to coexist with 
Cohen’s kappa of 0.29.  
 
Ten (33%) participants with hypertension and diabetes met diagnostic criteria for depression 
compared to 14 (30%) participants with hypertension only who met diagnostic criteria for 
depression (Table 2). A total of 18 (38%) participants with hypertension only met diagnostic 
criteria for panic disorder, and 11 (37%) with hypertension and diabetes met diagnostic criteria 
for panic disorder. There was no statistically significant difference in the prevalence of 
depression or panic disorder between participants with only hypertension and those with 
hypertension and diabetes. The diagnosis of hypertension only and hypertension comorbid with 
diabetes was not significantly associated with a diagnosis of PTSD. The diagnosis of 
hypertension only had a statistically significant association with agoraphobia. 
 
Quality of Life in the study sample 
The internal consistency of the domains was assessed through the Cronbach reliability 
coefficient. Cronbach's alpha values for psychological health, physical health, social 
relationships and environment are presented in Table 3. 









Mean 12.42 14.17 14.97 12.71 
Std. dev.  3.8669 3.4185 3.1289 2.9453 
Cronbach alpha 0.82 .80 .60 .79 
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Cronbach’s alpha for internal consistency reliability was shown to be acceptable for different 
WHOQOL-BREF domains (Table 3). DOM 1, physical health had a low mean score (12.42) 
indicative of poor physical health suggesting impairments in activities of daily living, low 
energy and fatigue, pain and discomfort and dependence on medicinal substances and medical 
aids. Similar to the physical health domain, DOM 4, environment had a low mean score 
indicative of poor QOL in the environment domain. This suggested poor financial resources, a 
poor sense of freedom, physical safety and security, home environment, health and social care 
and a poor physical environment. The social relationships domain, DOM 3, had a higher mean 
score 14.97 compared to all the domains. This result suggests good personal relationships, 
social support and sexual activity amongst adults living with hypertension and/or diabetes. 
 
Quality of life and the endorsement of Major depressive disorder and/or an Anxiety 
disorder 
The results show a statistically significant association between depression and and quality of 
life p=<0.01 (Table 4). Panic disorder had a statistically significant association with quality of 
life, physical domain. Post traumatic stress disorder had a statistically significant association 
with quality of life and psychological domain. 
Table 4: WHOQOL-BREF scores associated with common mental disorders 
Effect Physical domain Psychological 
domain 
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* indicates a statistically-significant Mann-Whitney test at p<0.05 
PTSD, posttraumatic stress disorder; GAD, generalised anxiety disorder 
	
DOM 1, physical health had a low mean score indicative of poor physical health suggesting 
impairments in activities of daily living, low energy and fatigue, pain and discomfort and 
dependence on medicinal substances and medical aids. Similar to DOM 1 (physical health), 
DOM 4 (environment) had a low mean score indicative of poor QOL in the environment 
domain. This indicated poor financial resources, a poor sense of freedom, physical safety and 
security, home environment, health and social care and a poor physical environment. The social 
relationships domain, DOM 3, had a higher mean score 14.97 compared to all the domains. 
This result suggests good personal relationships, social support and sexual activity amongst 
adults living with hypertension and/or diabetes. 
 
Quality of life and comorbid medical conditions 
DOM 1 (physical health) and DOM 4 (environment) have the lowest mean scores in participants 
living with other co-morbid medical conditions (Table 5). The other medical conditions 
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Table 5: Relationship between quality of life scores and the presence of other medical conditions in patients 
with hypertension and/or diabetes 
WHOQOL-BREF 
domains 
Other medical conditions 
 Yes (n=43) No (n=36) p value 
Physical  11.26 (3.85) 13.76 (3.57) <0.01* 
Psychological 13.58 (3.49) 14.76 (3.32) 0.09 
Social 14.45 (3.28) 15.67 (2.89) 0.18 
Environment 12.07 (3.04) 13.50 (2.69) 0.03* 
*indicates a statistically-significant (p<0.05) Mann-Whitney U test 
 
VISTAD and Quality of life 
The minimum score for the VISTAD was 0 and maximum was 10 with a mean of 3.96 and a 
Std. Deviation of 3.401.  
Figure 1: Simple bar count of total VISTAD score 
 
 
Table 6 shows that participants who endorsed VISTAD items had lower mean scores on all 
domains compared to participants who did not endorse VISTAD items. Table 6 shows that 
participants who endorsed VISTAD items had poor quality of life compared to participants who 
did not endorse VISTAD items. Participants who endorsed the sleep disturbance item on the 
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VISTAD had lower mean scores (Table 6) on the physical, psychological, social and 
environment domain compared to participants who did not endorse sleep disturbance. 
Table 6: WHOQOL-BREF Domains and VISTAD items 
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VISTAD scores and other comorbid medical conditions 
There was no statistically significant association between medical conditions and the VISTAD (Table 
7). 
Table 7: Other medical conditions and VISTAD scores 
Medical conditions    VISTAD Score N       Mean   Std. Dev Mann-Whitney p 
HIV                       no      67      3.84      3.401 
                   yes  11      4.73      3.467          
          p=.424     
          
Asthma         no   66      3.83      3.404  
        yes  12      4.67      3.447           
          p=.439 
Arthritis        no     66       3.79       3.422 
       yes  12       4.92       3.260                     
          p=.293 
Other medical conditions together     no  42       4.50       3.445 
                     yes  36       3.33       3.286 
         p=.132 
                                                            
 
DISCUSSION 
We found a prevalence of depression 32% for depression which is lower than previously 
reported by Alkhathami et al.6 of 48.7 in a primary health population living with hypertension 
and/or diabetes. Our findings were consistent with a South African study conducted by 
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Andersson et al.43 which found a prevalence of 31% in the South African province where our 
study was conducted.  
In a study sample of 40 patients with hypertension, Rubio-Guerra et al.44 reported that 23 
patients (57%) had depression which is higher than the number reported in our study. A 
systematic review and meta-analysis by Li et al.45 reported a summarized depression prevalence 
of 26.8% in people living with hypertension with prevalence rates ranging from 4.8% to 73.3%. 
Mahmood et al.46 reported higher prevalence rate to ours in a cross sectional study with a 40.1% 
prevalence rate of depression in hypertension.  
We found a statistically significant association between the diagnosis of depression and poor 
QOL. This was observed across the four domains; physical, psychological, social relationships 
and environment in participants living with hypertension and/or diabetes. This is consistent 
with findings by Goldney et al.8 who observed that people living with diabetes comorbid with 
depression have poor quality of life on all domains compared to those who have diabetes only 
without depression. Higher quality of life, according to Goldney et al.8 is experienced by people 
without diabetes, without depression compared to those with depression and diabetes. Overall, 
the sample of our study had poor quality of life across domains (physical, psychological, 
environment) except for the social relationships domain which was found to be higher. This is 
indicated satisfaction with personal relationships and social support. 
Agoraphobia had a statistically significant association with the diagnosis of hypertension, but 
not hypertension co-morbid with diabetes. Whilst few participants (10%) were diagnosed with 
agoraphobia, this was similar to 10.4% in an older population previously reported by Ritchie et 
al.47 Low prevalence rates of agoraphobia were also reported by the American Psychiatric 
Association (APA),48 noting that about 1.7% of adults and adolescents are diagnosed with 
agoraphobia every year. 
Similarly to agoraphobia, 10% of the study participants had a diagnosis of social phobia. Social 
phobia in adolescents has a prevalence of approximately 9% according to Burstein et al.49 
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According to the APA,48 the 12-month prevalence rates of social phobia in children and 
adolescents are comparable to those in adults. Based on this we could argue that the number 
reported in our study is consistent to with current reports on the prevalence of social phobia. 
Leichsenring and Leweke reported a higher prevalence rate (13%) in the American 
population.50 We found no association between the diagnosis of social phobia and hypertension 
and/or diabetes. This is consistent with findings made by Edwards and Mezuk who observed 
no evidence between a history of anxiety disorders, including social phobia and Type 2 
diabetes.51 Anxiety and depression, as reported by Edwards and Mezuk, have different 
biological mechanisms which may explain the difference in the relationship between these 
disorders (anxiety disorders and depression) and diabetes.51  
Panic disorder was the most observed diagnosis in this study sample with 32 (40%) participants 
diagnosed. Research evidence shows that panic disorder is also highly prevalent in other 
medical conditions. Reported rates include 40% in tinnitus52 29% in HIV,53 and 25% in chest 
pain patients.54 In hypertension, panic attacks and panic disorder are extremely common in 
patients receiving treatment in hospital settings.55 Li et al. reported a prevalence rate of panic 
disorder of 26.8% in patients diagnosed with hypertension.45 We found no statistically 
significant association between these conditions and hypertension in our study. This is 
consistent with previous research.55  
Post-traumatic stress disorder was the second most observed anxiety disorder in this study. 
Posttraumatic stress disorder, according to Seedat,56 is among the most prevalent compared to 
other anxiety disorders in terms of lifetime and 12-month prevalence rates documented in 
epidemiological studies.56 The authors recognize that people in South Africa are exposed to 
high levels of violence,57 which contributes to the development of PTSD. Balint et al. found a 
9% prevalence for PTSD in 70% of hypertensive patients who have had at least one traumatic 
event.58 In primary care, studies have recounted a prevalence of PTSD ranging from 2.0%–
39.1% in hypertensive patients.59 Also there is an increased prevalence of PTSD in Type 2 
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diabetes; and the relationship between PTSD and Type 2 diabetes remains significant when 
depression, depressive mood or exhaustion, anxiety, and somatization have been adjusted for, 
and also controlling for socio-demographic characteristics.60 The relationship between 
hypertension and/or diabetes and PTSD was not statistically significant in our study.  
 
Generalized anxiety disorder (GAD) was observed in 14 (17%) of the study participants. 
Grigsby et al. reported that GAD was present in 14% of their study sample of people living with 
diabetes,61 and Whitworth et al. reported a current prevalence of 6.5% and a lifetime prevalence 
of 23%.48 Revicki et al.62 reported that GAD is highly prevalent but under-diagnosed. 
Generalised anxiety disorder requires early identification and treatment in order to reduce the 
extent of impairment and disability.63 Consistent with our findings, previous studies found no 
statistically significant association between GAD symptoms and hypertension.64  
People living with hypertension and/or diabetes comorbid with anxiety disorders had poor 
quality of life compared to participants without anxiety anxiety disorders. There was a 
statistically significant association with PTSD and impairment on the psychological domain.  
This indicates poor satisfaction with bodily appearance, presence of negative feelings and low 
self-esteem. Furthermore, this could suggest impairments with ability to think, poor memory 
and concentration. Previous studies have established that people living with hypertension 
and/or diabetes have an increased prevalence of psychological health problems.65,25,63,66 
Different factors can influence the results on the psychological domain. These factors include 
trauma and violence,57 post-traumatic stress disorder,67 and the generally high prevalence of 
mental disorders in South Africa. Also, environmental or social factors in poverty stricken 
communities might increase psychological distress.66 Generalized anxiety disorder had 
significant association with poor physical, social relationships and environment domain.  
Chronic medical conditions such as type 2 diabetes are known to influence, the social and 
psychological domain as a result of the nature of the disease and its associated complications. 
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This imposes demands on patients and families which can be burdensome.68 A study with an 
elderly population found low scores on physical, psychological and environment domain 
compared to participants with diabetes.69 The relationship between hypertension, diabetes and 
quality of life was not statistically significant in the study by Kumar et al.69 Some of the research 
findings using the on QOL amongst people living with hypertension has been conflicting. In 
our study, we found that overall, the study participants had higher satisfaction in the social 
relationships domain compared to physical, psychological and environment domain; whereas, 
Oza et al.16 reported the social domain to be the lowest with hypertension. Consistent with 
previous some research, people living with hypertension and/or diabetes have poor quality life 
on the physical70,71 psychological70 and environment domains.72 Consistent with the findings 
on M.I.N.I based diagnosis of depression and anxiety disorders, participants who endorsed 
depression and anxiety items on the VISTAD reported poor QOL compared to participants who 
did not endorse any depression or anxiety disorder items. This finding showed that the VISTAD 
has significant correlation with the WHOQOL-BREF which shows that the VISTAD has 
acceptable psychometric properties.  
A relatively small number of participants in our study reported possible dependence and 
harmful or hazardous levels of drinking. The relatively low levels of alcohol use found in our 
study are inconsistent with findings of previous studies in other countries and South Africa 
which reports much higher levels.73,74 A South African study conducted by Bhana, Rathod, 
Selohiwe, Kathree, and Petersen75 found high levels of abstinence from alcohol amongst 
patients with diabetes (65%) and this is consistent with observations of our study. Whilst 
alcohol and drug use seemed to be relatively low, more than 15% admitted use of drugs or 
problematic use of alcohol, future studies can further investigate in larger samples, the patterns 
of alcohol and drug use and the association with hypertension and/or diabetes and depression 
and anxiety disorders.  
We found a statistically significant association between two VISTAD items, irritability and 
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suicidal ideation and drug related problems. The additional eight VISTAD items had no 
association with alcohol and/ drug related problems. From this finding, we can conclude that 
the VISTAD only screens for depression and anxiety disorders symptoms and not drug and 
alcohol related problems. 
Our findings of no significant association between anxiety disorders and hypertension are 
consistent with other reports.76,77 However, it is worth noting the conflicting findings on the 
association between hypertension and anxiety disorders.78 Rigorous data on larger samples are 
needed in order to validate the growing body of research reporting on this association.79,80  
 
STUDY STRENGTHS AND LIMITATIONS 
We used a valid and reliable diagnostic tool, the M.I.N.I to diagnose and report the number of 
people living with depression and anxiety disorders rather than screening tools only which 
might over-estimate the prevalence of depression.81 However, the M.I.N.I has not been 
specifically validated for use at primary care with people living with hypertension and/or 
diabetes. It is also important to acknowledge that patients could have difficulty in distinguishing 
between hypoglycemia and anxiety symptoms such as dizziness, shakiness, lack of coordination 
and heart palpitations,82 which might lead to over-reporting of anxiety, perhaps explaining the 
high number of participants meeting criteria for panic disorder. The data presented in this study 
pertains to the diagnosis of hypertension and/or diabetes, and the type of diabetes is not 
differentiated. Future studies could differentiate prevalence rates according to the type of 
diabetes and have two separate groups, diabetes only and hypertension only in order to compare 
prevalence of depression in the conditions. As a result of the small sample, findings of this 
study cannot be generalized to individuals attending primary health care. Furthermore, with 
reference to race, gender and level of education the sample of our study was not a nationally 
representative sample of primary health care patients living with hypertension and/or diabetes. 
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It is worth noting that Eastern Cape is a predominantly black province and that the sample is 
fairly representative of this region.  
CONCLUSION 
Depression and anxiety disorders influence quality of life of people living with hypertension 
and anxiety disorders. Whilst alcohol and drug use seemed to be relatively low, more than 15% 
admitted use of drugs or problematic use of alcohol. The findings of this study underscore the 
need to have mental health care integrated into primary health for people living with 
hypertension and/or diabetes.  
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CHAPTER FOUR 
This chapter has been published in the African Journal of Primary Health Care & Family Medicine. 
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Current literature demonstrates that hypertension and diabetes have emerged as a major medical 
and public burden globally.1,2,3,4 South Africa is burdened with a high prevalence of hypertension 
and diabetes. There are 2.3 million people living with diabetes in South Africa,5 and 30% of the 
adult population is living with hypertension.6 Furthermore, hypertension and diabetes account 
for 17 million visits to health facilities in South Africa every year.1
The diabetes and hypertension burden is further complicated by the increasingly high co-
morbidity with depression and anxiety disorders. Kumar and Clark7 argue that chronic diseases 
have psychological sequelae; however, these remain largely undetected and untreated at primary 
health care.8,9,10 Patients may be aware of their emotional state; however, they may be unable to 
describe accurately their subjective experience, according to Aitken.11 In addition, inadequate 
levels of mental health literacy, for both health care workers12 and patients, have been well 
established in research.13
When clinicians do attempt to screen for mental disorders in patients with hypertension and/or 
diabetes, primary health care facilities are faced with barriers such as insufficient human and 
material resources, lack of assessment instruments that can be appropriately applied to the diverse 
range of cultural and language groupings in South Africa, and communication difficulties which 
lead to misunderstandings, misdiagnosis and/or inappropriate treatment. In addition to the 
above-mentioned barriers, pencil and paper tests are often not available or have to be read aloud 
Background: Depression and anxiety disorders remain poorly detected at primary health care, 
particularly in patients with hypertension and/or diabetes. A visual screening tool for anxiety 
disorders and depression (VISTAD) has been developed, but not validated.
Aim: To validate the VISTAD in primary health care participants diagnosed with hypertension 
and/or diabetes.
Setting: Participants were recruited from five primary health care centres in the Eastern Cape, 
South Africa (urban, peri-urban and rural).
Methods: The study used a cross-sectional study design to validate the VISTAD. The VISTAD 
was validated against the International Neuropsychiatric Interview (M.I.N.I) using field 
testing. A demographic questionnaire was used to collect data on socio-economic variables.
Results: Sixty-nine (87%) females and 10 (13%) males with a mean age of 49 (SD 8.6844) 
participated in the study. Fifty black people (63%), 16 mixed race people (20%) and 13 white 
people (16%) participated in the study. The majority of the participants (77%) did not complete 
high school. The area under curve score (AUC) for the VISTAD in screening for depression 
was 0.91, and for anxiety disorders, 0.87 post-traumatic stress disorder, 0.87 panic disorder, 
0.85 social phobia, 0.88 agoraphobia, and 0.83 generalised anxiety disorder revealing acceptable 
psychometric properties.
Conclusion: The use of the VISTAD as a screening tool at primary health care in people living 
with hypertension and/or diabetes is recommended. The VISTAD could, therefore, play a key 
role in the prevention and early treatment of individuals diagnosed with hypertension and/or 
diabetes across cultures and levels of education. The VISTAD needs to be validated in a large 
population representative of primary care patients diagnosed with hypertension and/or 
diabetes.
The validation of the visual screening tool 
for anxiety disorders and depression in 
hypertension and/or diabetes
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to illiterate patients.14 Availability of appropriate tools at 
primary health care could therefore contribute to the quality 
of detection and management of mental disorders, particularly 
in developing countries. Visual screening tools for depression 
and anxiety disorders could possibly circumvent the 
challenges posed by cultural, language, educational and time 
factors. This has been shown by Akena et al.15 who developed 
a visual screening tool for depression in patients living with 
HIV and/or AIDS in Uganda. However, the screening tool 
developed by Akena et al.15 does not screen for anxiety 
disorders. Screening for depression, according to Katon 
et al.,16 should also include anxiety disorders as these often 
coexist in patients living with chronic physical conditions.
The use of pictures in aiding patients to describe emotions 
and thoughts has been well established in psychology. 
Psychological tests, referred to as projectives, such as the 
thematic apperception test (TAT),17 make use of drawings in 
order to allow access to unconscious thoughts, emotional life 
and internal dynamics – revealing hidden materials that 
clients are unable to disclose or unwilling to disclose. Ogle, 
Koen and Niehaus developed a visual screening tool for 
anxiety disorders and depression (VISTAD) using drawings 
based on the hospital anxiety and depression scale (HADS). 
The visual screening tool is referred to as the VISTAD. It 
includes depression items such as sleep disturbance, feeling 
miserable and sad, appetite and feeling life is not worth 
living, as well as anxiety items such as feeling frightened or 
having panic feelings for no reason, feeling frightened when 
going out of the house alone, getting palpitations or 
sensations ‘butterflies’ in stomach or chest, more irritable 
than usual and worrying thoughts. The VISTAD, however, 
has not been validated for use in primary health care.
The aim of the study was to validate the VISTAD as a 
screening tool for use in primary health care in individuals 
diagnosed with hypertension and/or diabetes and as a tool 
that can be used effectively in a time- and resource-




The study used a cross-sectional study design for validating 
the newly developed VISTAD.
Setting
The study was conducted in five primary health care centres 
in the Eastern Cape, South Africa. These primary health care 
centres provide health care services to two urban areas, 
KwaMagxaki, a predominantly black suburb, and Algoa 
Park, a mixed suburb, mixed race and white population, in 
Port Elizabeth; one peri-urban area in Uitenhage, 
predominantly black population; and two rural communities, 
KwaNonqubela, a black community, and Wentzel Park, a 
mixed race community in Alexandria, Eastern Cape.
Sampling strategy
Purposive sampling was utilised to recruit participants who 
were able to provide informed consent. Individuals were 
recruited while they were at the settings for their routine 
scheduled visit. Individuals between the ages of 18 and 60, 
diagnosed with diabetes and/or hypertension, were eligible 
for the study. Individuals known to have visual and hearing 
impairments, and intellectual disability were excluded from 
the study.
The principal researcher explained the purpose of the study 
and requested individuals who were interested in 
participating in the study to indicate their interest. Those 
who indicated an interest or wanted to get more information 
were interviewed in a private setting and provided with 
more details on the study.
Data collection
A demographic questionnaire was utilised to gather 
information about gender, age, race, marital status, level of 
education, employment status, family income and medical 
conditions. A short structured diagnostic interview, the 
International Neuropsychiatric Interview (M.I.N.I),18 was 
used as a gold standard in the validation of the VISTAD. It 
covers 17 Axis I disorders that include mood, anxiety, 
substance use, psychotic and eating disorders, and it also has 
a suicidality module and one Axis-II disorder, antisocial 
personality disorder.18 Sheehan et al.18 found the M.I.N.I to be 
a reliable and valid diagnostic tool, and it has been used in 
South African studies.19,20,21,22 The development of the VISTAD 
is discussed in detail in Ogle, Koen and Niehaus.23 In the 
VISTAD, a score of 1 is allocated when a participant endorses 
an abnormal state drawing and 0 when none of the abnormal 
state symptoms are endorsed. The maximum score that could 
be obtained on the VISTAD is 10.
Data analysis
Descriptive statistics were used to describe demographic 
data. The M.I.N.I was used to categorise cases and non-cases 
of depression (major depressive episode) and anxiety 
disorders, that is, agoraphobia, generalised anxiety disorder 
(GAD), panic disorder, post-traumatic stress disorder (PTSD) 
and social phobia, excluding obsessive–compulsive disorder. 
The impact of education, employment and gender on the 
performance of VISTAD was investigated. Coefficient of 
correlation (coef.) indicated the correlation between the 
above-mentioned variables. The sensitivity and specificity 
and likelihood ratios (LR) were estimated. Sensitivity and 
specificity was calculated based on leave-one-out cross 
validation. Cut-off scores were informed by high specificity 
scores and moderate sensitivity scores. With a high specificity, 
the truly positives represent the mental disorder being 
screened for and not another condition, such as diabetes or 
hypertension.
The plot of sensitivity versus specificity is referred to as the 
receiver operating characteristics (ROC).24 The area under the 
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curve (AUC) which is an effective measure of diagnostic test 
accuracy24 was used for interpretations of the data. An AUC 
value of 0.50–0.70 is considered low accuracy, 0.70–0.90 is 
considered moderate accuracy and 0.90 is considered high 
accuracy.25 Linear discriminant analysis was used to predict 
the disorder outcomes with the VISTAD drawing outcomes 
as predictors. All data analyses were done with STATA, 
version 14.
Ethical considerations
Ethical approval was granted by the University of 
Stellenbosch’s Faculty of Medicine and Health Sciences 
Human Research Ethics Committee (Reference number: 
S14/11/262). Permission to conduct the study at the primary 
care centres was obtained from the Eastern Cape Department 
of Health, South Africa
Results
Demographics
Eighty-one participants from primary health care participated 
in the validation of the VISTAD. All the participants 
consented and participated in this study. However, out of the 
81 participants, one declined to continue with completing the 
interview reporting that the VISTAD depicted his life, and it 
was painful to look at the images.
In this study, we used demographic data of 79 participants as 
there was missing information from two participants. The 
majority of the participants were females, 69 (87%), with 10 
(13%) males. Race distribution on the basis of gender showed 
that there were 43 black females, 15 mixed race females and 
11 white females, and seven black males, two white males 
and one mixed race male. The mean age of the participants 
was 49, with standard deviation 8.6844 and minimum age 22 
and maximum 60. Socio-demographic variables and related 
factors are set out in Table 1.
Accuracy of the visual screening tool for anxiety 
disorders and depression
The AUC determined the accuracy of the VISTAD. The AUC 
in screening for depression is shown in Figure 1, PTSD in 
Figure 2, panic disorder in Figure 3, GAD in Figure 4, social 
phobia in Figure 5 and agoraphobia in Figure 6. The AUC 
score for depression shows a high accuracy of 0.91.
The best cut-off scores were based on high specificity and 
moderate sensitivity. At a cut-off score of 6, the specificity 
was 90.91, and sensitivity was 72.00%, with 85% correctly 
classified cases. The specificity was 90.91 and sensitivity was 
60.00%, with 81.25% correctly classified cases at a cut-off 
score of 7.
The area under curve for PTSD was 0.87. At a cut-off point of 
6 for PTSD, there were 68% correctly classified cases with a 
specificity of 72.22% and a sensitivity of 37%. Similar to 
PTSD, the area under curve for panic disorder was 0.87, 
which indicated moderate accuracy. The specificity of the 
VISTAD at a cut-off point of 6 was 81.25%, with a sensitivity 
of 43.75%.
Agoraphobia had a specificity of 73.61%. Social phobia had a 
specificity of 72.22% at a cut-off score of 6. Generalised 
anxiety disorder had a specificity of 74.63%, with 70% 
correctly classified cases.
Fundamental to the validation of the VISTAD is the 
investigation of whether education levels, socio-economic 
status and gender have an impact on the performance of the 
VISTAD. Table 2 presents the impact of level of education, 




In this study, we validated the VISTAD against the M.I.N.I. at 
primary health care in participants diagnosed with 
hypertension and/or diabetes. The VISTAD demonstrated 











Black people 50 63
Mixed race 16 20
White people 13 17
Education
No education 2 3
Primary level of education (Grades 1–6) 25 32
Senior level of education (Grades 7–11) 33 42
Matric (Grade 12) 15 19





Hypertension only 47 59
Diabetes only 1 1
Hypertension and diabetes 31 39
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high accuracy in detecting depression in participants with 
hypertension and/or diabetes. The AUC of the VSTAD was 
0.91 in screening for depression. At a cut-off score of 6, the 
VISTAD had satisfactory accuracy in classifying cases. This is 
similar to that of the HADS which the VISTAD is based on. At 
a cut-off score of 7, the HADS depression subscale provided 
the best balance between a sensitivity of 0.86 and a specificity 
of 0.81 in cancer patients.26 In our study, the best balance was 
at a cut-off score of 6 with a sensitivity of 0.72 and a specificity 
of 0.91, with 85% of the cases classified correctly. The accuracy 
of the VISTAD is also similar to that of other widely used 
traditional screening tools, such as the Patient Health 
Questionnaire (PHQ), with an AUC of 0.88 at a higher cut-off 
score in patients with type II diabetes and/or coronary heart 
disease in primary care,27 and the Kessler Scale (K10) for either 
anxiety or depression28 and CES-D, K-10 and PHQ-9 and with 
AUC ranging from 0.82 to 0.9615 in people living with HIV.
The VISTAD had a higher AUC score compared to the recently 
validated WHO-5 for use in screening for depression in adults 
with diabetes. The AUC scores for WHO-5 in the validation 
study by Halliday et al.29 ranged between 0.85 and 0.88, which 
demonstrated that the WHO-5 has moderate accuracy in 
screening for depression. This demonstrates that the VISTAD is 
a valuable tool for detecting depression. The optimal cut-off 
score chosen for depression was 6 in this study. This is in line 
with the current practice of selecting higher cut-off scores to 
indicate the presence of depression.28,29 Similar to screening for 
Posterior P (yes) = 0.3726


















AUC = 0.91 (0.84–0.98)
FIGURE 1: Receiver operating curves of the visual screening tool for anxiety 
disorders and depression for depression.
Posterior P (yes) = 0.5606



















FIGURE 2: Receiver operating curves of the visual screening tool for anxiety 
disorders and depression for post-traumatic stress disorder.
Posterior P (yes) = 0.643



















FIGURE 3: Receiver operating curves of the visual screening tool for anxiety 
disorders and depression for panic disorder.
Posterior P (yes) = 0.5776



















FIGURE 4: Receiver operating curves of the visual screening tool for anxiety 
disorders and depression for generalised anxiety disorder.
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depression, the optimal cut-off score chosen for anxiety disorders 
was 6. The AUC for anxiety disorders was in the moderate 
range. This indicates that the accuracy of the VISTAD was better 
for depression than for anxiety. This is consistent with findings 
made in the meta-analysis conducted by Vodemaier and 
Millman26 on other screening tools. Previous research has also 
established a similar pattern. For example, GAD 7 showed 
lower sensitivity and specificity levels when compared to 
screening tools for depression.28 Makanjuola et al.30 also reported 
lower AUC values in Nigeria for K-6 and the General Health 
Questionnaire (GHQ-12). K-6 and GHQ-12 are sensitive and 
specific screening tools widely used and recommended for use 
in the screening for depression and/or anxiety disorders in 
primary health care and community samples.
Newly developed screening tools have also been 
recommended for use in patients with chronic medical 
conditions. A Ugandan study recommended the use of a 
visual screening tool for depression.15 This was based on its 
accuracy in detecting depression in people living with HIV. 
However, a study by Puertas31 did not recommend the use of 
visual screening tools as it found the FACES test to have low 
accuracy. The FACES test, according to Puertas, is a visual 
analogue scale representation of mood, consisting of seven 
graded faces from happiest mood to saddest mood. Akena15 
argues that screening tools, such as the FACES test, have 
often depended on a single facial picture depicting emotions 
ranging from a happy face to an extremely sad face. 
Participants with lower literacy levels struggle to comprehend 
the FACES screening tool according to Puertas31 Previous 
research has established that education has an impact on 
people’s ability to comprehend and complete screening 
tools.32,33 Some, according to Snaith,34 are ashamed and 
pretend to answer questions and respond in a haphazard 
manner. This study demonstrated that education had no 
impact on the participants’ ability to comprehend and 
complete the VISTAD. The findings on the education and 
performance of the VISTAD are consistent with previous 
research by Akena et al.15 Furthermore, the socio-economic 
status had no impact on the participants’ ability to understand 
and complete the VISTAD. The majority of participants in 
this study were of low socio-economic status.
Based on the M.I.N.I, we noted a high prevalence of common 
mental disorders in this study. For example, depression had a 
prevalence of 32%. This is consistent with the findings of 
Jacob and Kostev’s study,35 which reported a prevalence of 
33.7% in women and 26.8% in men diagnosed with diabetes. 
Cols-Sagarra et al.36 reported a higher prevalence of 43.4% in 
women with diabetes at primary health care. A prevalence of 
31.4% was reported in a study conducted in rural and urban 
parts of the Eastern Cape, South Africa,37 and this finding is 
consistent with the prevalence observed in our study.
Anxiety disorders such as panic disorder and PTSD had a 
high prevalence, with panic disorder at 40% and PTSD at 
33%. Other studies have found a significantly higher 
prevalence of panic disorder in hypertensive patients.38 Also, 
in primary care, studies have observed a prevalence of PTSD 
ranging from 2.0% to 39.1% in hypertensive patients.39 Post-












0.0 0.1 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.2
AUC = 0.85 (0.72–0.98)







FIGURE 5: Receiver operating curves of the visual screening tool for anxiety 
disorders and depression for social phobia.
Posterior P (yes) = 0.46780




















FIGURE 6: Receiver operating curves of the visual screening tool for anxiety 
disorders and depression for agoraphobia.
TABLE 2: Impact of education, gender and employment status on the 
performance of the visual screening tool for anxiety disorders and depression.
Variable Coef. SE T p > |t| 95% CI
Level of education
Primary -0.7505694 3.557147 -0.21 0.833 -7.841612–6.340473
Senior -0.6239653 3.507459 -0.18 0.859 -7.615957–6.368026
Matric -2.326809 3.619307 -0.64 0.522 -9.541764–4.888147
Post-matric 0.0663401 4.089943 0.02 0.987 -8.086812–8.219493
Gender
Male -3.715155 1.795807 -2.07 0.042 -7.295031– -0.1352794
Employment
Yes 0.4993359 1.26012 0.40 0.693 -2.012668 –3.01134
_cons 4.808826 3.425357 1.40 0.165 -2.019499–11.63715
/sigma 4.344278 0.4488455 3.449521–5.239035
CI, confidence interval; SE, standard error; coef., coefficient of correlation; cons, coefficient 
estimate; sigma, standard deviation.
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most prevalent compared to other anxiety disorders in terms 
of lifetime and 12-month prevalence rates documented in 
epidemiological studies. The number of participants who 
had a positive diagnosis of a common mental disorder was 
high. This observation is consistent with previous research 
findings.39,41,42 Data on larger samples are needed to determine 
the prevalence of depression and anxiety disorders in 
primary care patients with hypertension and/or diabetes.
Strengths and limitations
This is the first study to develop and validate a visual 
screening tool for both depression and anxiety disorders in 
primary health care participants diagnosed with hypertension 
and/or diabetes in South Africa. Furthermore, the use of the 
M.I.N.I in the study was not limited to the depression 
module, and the anxiety disorder module was also 
administered, except for obsessive–compulsive disorder 
module. The administration of the M.I.N.I depression 
module only might artificially inflate the extent of the 
correlations as some participants with depression might have 
been better diagnosed with another disorder, such as anxiety 
disorders.15 Also, this could lead to a false accuracy of the 
visual screening tool. The strength of the study was enhanced 
by the inclusion of five different primary health care sites, 
which serve urban, peri-urban and rural population.
Because of the small size of the sample, we cannot generalise 
the findings of the study to all individuals attending primary 
health care. Thus, future research is needed to validate 
the VISTAD in a large primary health care population. 
Furthermore, the use of the VISTAD in primary health care 
with speech impairments and intellectual impairments needs 
further investigation. A further limitation is that this study 
was informed by the DSM-IV nosology. For example, PTSD is 
no longer described as an anxiety disorder in the current 
DSM-V, but as a trauma- and stressor-related disorder.
Conclusion
The visual screening tool is referred to as the VISTAD. The 
VISTAD is accurate in detecting depression and anxiety 
disorders in primary health care participants diagnosed with 
diabetes and/or hypertension. The use of the VISTAD is 
recommended as a screening tool for depression and anxiety 
disorders at primary care level in patients with hypertension 
and/or diabetes. However, the VISTAD needs to be validated 
in a large population of primary care patients diagnosed with 
hypertension and/or diabetes.
Acknowledgements
The authors would like to thank Prof. Martin Kidd for doing 
data analysis and Mrs Jane Metelo-Liquito for doing the 
drawings.
Competing interests
The authors declare that they have no conflicts of interest to 
disclose. Neither personal nor financial relationship may 
have inappropriately influenced them in writing this article.
Authors’ contributions
This article is produced from research that will be submitted 
for a PhD in Psychiatry. Z.O. is the principal researcher. Z.O. 
collected data and produced the first draft of the article. L.K. 
is the research supervisor and contributed to the article 
review. D.J.H.N. is the co-supervisor and contributed to the 
article review.
References
 1. Department of Health Republic of South Africa. Strategic plan for prevention 
and control of non-communicable diseases 2013–17. 2013 [cited 2017 Sep] 
Available from: http://www.hsrc.ac.za/uploads/pageContent/3893/NCDs%20
STRAT%20PLAN%20%20CONTENT%208%20april%20proof.pdf
 2. Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension 
in Southeast Asian and African regions: Need for effective strategies for prevention 
and control in primary health care settings. Int J Hypertens. 2013;2013:1–14. 
https://doi.org/10.1155/2013/409083
 3. Mutowo MP, Lorgelly PK, Laxy M, et al. The hospitalization costs of diabetes and 
hypertension complications in Zimbabwe: Estimations and correlations. J Diabetes 
Res. 2016;2016:1–9. https://doi.org/10.1155/2016/9754230
 4. Tripathy JP, Thakur JS, Jeet G, Jain S. Prevalence and determinants of comorbid 
diabetes and hypertension: Evidence from non communicable disease risk factor 
STEPS survey, India. Diabetes Metab Syndr. 2017;11:S459–S465. https://doi.
org/10.1016-/j.dsx.2017.03.036.
 5. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: 
IDF; 2015.
 6. Kandala NB, Tigbe W, Manda SOM, Stranges S. Geographic variation of 
hypertension in sub-Saharan Africa: A case study of South Africa. Am J Hypertens. 
2013;26(3):382–391. https://doi.org/10.1093/ajh/hps063
 7. Kumar P, Clark ML. Kumar and Clark’s clinical medicine. 9th ed. Edinburgh: 
Saunders; 2017.
 8. Chou SP, Huang B, Goldstein R, Grant BF. Temporal associations between physical 
illnesses and mental disorders--results from the Wave 2 National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC). Compr Psychiatry. 
2013;54(6):627–638. https://doi.org/10.1016/j.comppsych.2012.12.020
 9. Lotfi L, Flyckt L, Krakau I, Mårtensson B, Nilsson GH. Undetected depression in 
primary healthcare: Occurrence, severity and co-morbidity in a two-stage 
procedure of opportunistic screening. Nord J Psychiatry. 2010;64(6):421–427. 
https://doi.org/10.3109/08039481003786378
10. Petersen I, Lund C. Mental health service delivery in South Africa from 2000 to 
2010: One step forward, one step back. S Afr Med J. 2011;101(10):751–757. 
https://doi.org/10.7196/samj.4841
11. Aitken RCB. Measurement of feelings using visual analogue scales. Proc R Soc 
Med. 1969;62:989–993.
12. Ganasen KA, Parker S, Hugo CJ, Stein DJ, Emsley RA, Seedat S. Mental health 
literacy: Focus on developing countries. Afr J Psychiatry. 2008;11:23–28. https://
doi.org/10.4314/ajpsy.v11i1.30251
13.  Cheung YT, Ong YY, Ng T, et al. Assessment of mental health literacy in patients 
with breast cancer. J Oncol Pharm Pract. 2016;22(3):437–447. https://doi.
org/10.1177/1078155215587541
14. Goldberg DP, Prisciandaro JJ, Williams P. The primary health care version of ICD-11: 
The detection of common mental disorders in general medical settings. Gen Hosp 
Psychiatry. 2012;34:665–670. https://doi.org/10.1016/j.genhosppsych.2012.06.006
15. Akena D, Joska J, Obuku E, Stein DJ. Sensitivity and specificity of clinician 
administered screening instruments in detecting depression among HIV-positive 
individuals in Uganda. AIDS Care. 2013;25(10):1245–52. https://doi.org/10.1080/
09540121.2013.764385
16. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical 
symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 
2007;29:147–155. https://doi.org/10.1016/j.genhosppsych.2006.11.005
17. Murray H. Thematic apperception test manual. Cambridge, MA: Harvard 
University; 1943.
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The MINI-International 
Neuropsychiatric Interview (M.I.N.I.): The development and validation of a 
structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 
1998;59(20):20–33.
19. Andersen L, Kagee A, O’Cleirigh C, Safren S, Joska J. Understanding the experience 
and manifestation of depression in people living with HIV/AIDS in South Africa. 
AIDS Care. 2015;27(1):59–62. https://doi.org/10.1080/09540121.2014.951306
20. Kader R, Seedat S, Parry C, Koch R. The relationship between substance abuse, 
health status and health behaviours of patients attending HIV clinics. Department 
of Psychiatry, University of Stellenbosch, Cape Town, South Africa; 2013.
21. Myer L, Smit J, Roux LL, Parker S, Stein DJ, Seedat S. Common mental disorders 
among HIV-infected individuals in South Africa: Prevalence, predictors, and 
validation of brief psychiatric rating scales. AIDS Patient Care STDs. 2008;22(2):147–
158. https://doi.org/10.1089/apc.2007.0102
22. Spies S, Kader K, Kidd M, et al. Validity of the K-10 in detecting DSM-IV-defined 
depression and anxiety disorders among HIV infected individuals. AIDS Care. 
2009;21(9):1163–1168. https://doi.org/10.1080/09540120902729965
82
Stellenbosch University  https://scholar.sun.ac.za
Page 7 of 7 Original Research
http://www.phcfm.org Open Access
23. Ogle Z, Koen L, Niehaus DJH. The development of the visual screening tool for 
anxiety disorders and depression: Addressing barriers to screening for depression 
and anxiety disorders in hypertension and/or diabetes. Afr J Prim Care Fam Med. 
2018;10(1):a1721. https://doi.org/10.4102/phcfm.V10il.1721
24. Hanley JA, McNeil BJ. The meaning and use of the area under curve operating 
characteristic (ROC) curve. Radiology. 1982;143(1):29–36. https://doi.org/10.1148/
radiology.143.1.7063747
25. Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of 
diagnostic test properties. Clinical example of sepsis. Intensive Care Med. 
2003;29(7):1043–1051. https://doi.org/10.1007/s00134-003-1761-8
26. Vodemaier A, Millman RD. Accuracy of the Hospital Anxiety and Depression Scale as 
a screening tool in cancer patients: A systematic review and meta-analysis. Support 
Care Cancer. 2011;19:1899–1908. https://doi.org/10.1007/s00520-011-1251-4
27. Van der Zwaan, GL, Dijk SEM, Adriaanse MC, et al. Diagnostic accuracy of the 
Patient Health Questionnaire-9 for assessment of depression in type II diabetes 
mellitus and/or coronary heart disease in primary care. J Affect Disord. 
2016;190:68–74. https://doi.org/10.1016/j.jad.2015.09.045
28. Conway A, Sheridan J, Maddicks-Law J, et al. Accuracy of anxiety and depression 
screening tools in heart transplant recipients. Appl Nurs Res. 2016;32:177–181. 
https://doi.org/10.1016/j.apnr.2016.07.015
29. Halliday JA, Hendrieck C, Busija L, et al. Validation of the WHO-5 as a first-step 
screening instrument for depression in adults with diabetes: Results from 
Diabetes MILES – Australia. Diabetes Res Clin Pract. 2017;132:27–35. https://doi.
org/10.1016/ j. diabres.2017.07.005
30. Makanjuola VA, Onyeama M, Nuhu FT, Kola L, Gureje O. Validation of short screening 
tools for common mental disorders in Nigerian general practices. Gen Hosp 
Psychiatry. 2014;36:325–329. https://doi.org/10.1016/j.genhosppsych.2013.12.010
31. Puertas G, Patel V, Marshall T. Are visual measures of mood superior to 
questionnaire measures in non-Western settings? Soc Psychiatry Psychiatr 
Epidemiol. 2004;39:662–666. https://doi.org/10.1007/s00127-004-0800-2
32. Reddy P, Philpot B, Ford D, Dunbar JA. Identification of depression in diabetes: The 
efficacy of the PHQ-9 and the HADS-D. Br J Gen Pract 2010;60:e239–e245. https://
doi.org/10.3399/bjgp10X502128
33. Hanlon C, Luitel NP, Kathree T, et al. Challenges and opportunities for implementing 
integrated mental health care: A district level situation analysis from five low- and 
middle-income countries. PLoS One. 2014;9(2):e88437. https://doi.org/10.1371/
journal.pone.0088437
34. Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes. 
2003;1:29. https://doi.org/10.1186/1477-7525-1-29
35. Jacob L, Kostev, K. Prevalence of depression in type 2 diabetes patients in German 
primary care practices. J Diabetes Complications. 2016;30:432–437. https://doi.
org/10.1016/j.jdiacomp.2015.12.013
36. Cols-Sagarra C, López-Simarro F, Alonso-Fernández M, et al. Prevalence of 
depression in patients with type 2 diabetes attended in primary care in Spain. Prim 
Care Diabetes. 2016;10(5):369–375. https://doi.org/10.1016/j.pcd.2016.02.003
37. Andersson LMC, Schierenbeck I, Strumpher J, et al. Help-seeking behaviour, 
barriers to care and experiences of care among persons with depression in 
Eastern Cape, South Africa. J Affect Disord. 2013;151(2):439–448. https://doi.
org/10.1016/j.jad.2013.06.022i
38. Davies SJC, Ghahramani P, Jackson PR, et al. Association of panic disorder and 
panic attacks with hypertension. Am J Med. 1999;107:310–316. https://doi.
org/10.1016/S0002-9343(99)00237-5
39. Greene T, Neria Y, Gross R. Prevalence, detection and correlates of PTSD in the 
primary care setting: A systematic review. J Clin Psychol Med Settings. 
2016;23:160–180. https://doi.org/10.1007/s10880-016-9449-8
40. Seedat S. Guideline: Posttraumatic stress disorder. S Afr J Psychiatr. 
2013;19(3):187–191. https://doi.org/10.4102/sajpsychiatry.v19i3.952
41. Roy T, Llyod CE. Epidemiology of depression and diabetes: A systematic review. 
J Affect Disord. 2012;142(Suppl 1):S8–S21. https://doi.org/10.1016/S0165-
0327(12)70004-6
42. Rubio-Guerra AF, Rodriguez-Lopez L, Vargas-Ayala G, Huerta-Ramirez S, Serna DC, 
Lozano-Nuevo JJ. Depression increases the risk for uncontrolled hypertension. Exp 
Clin Cardiol. 2013;18(1):10–12.
83
Stellenbosch University  https://scholar.sun.ac.za
Chapter four described the validation of the visual screening tool for anxiety disorders and 
depression (VISTAD) in primary care patients living with hypertension and/or diabetes. This 
section presents additional data on the validation of the VISTAD.  
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ABSTRACT 
Background: Depression and anxiety disorders remain poorly detected at primary health care, 
particularly in patients with hypertension and/or diabetes. A visual screening tool for anxiety 
disorders and depression (VISTAD) has been developed, however not validated.  
Aim: To validate the VISTAD in primary health care participants diagnosed with hypertension 
and/or diabetes.  
Setting: Participants were recruited from five primary health care centres in the Eastern Cape, 
South Africa (urban, peri-urban and rural).  
Methods: The study used a cross-sectional study design to validate the VISTAD. The VISTAD 
was validated against the MINI International Neuropsychiatric Interview (M.I.N.I) using field 
testing. A demographic questionnaire was used to collect data on socio-economic variables. 
Results: Sixty-nine (87%) females and ten (13%) males with a mean age of 49 (SD 8.6844) 
participated in the study. Fifty black people (63%), 16 mixed ancestry people (20%) and 13 
white people (16%) participated in the study. The majority of the participants (77%) did not 
complete high school. The area under curve score (AUC) for the VISTAD in screening for 
depression was 0.91, and for anxiety disorders, 0.87 post-traumatic stress disorder, 0.87 panic 
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disorder, 0.85 social phobia, 0.88 agoraphobia, and 0.83 generalised anxiety disorder revealing 
acceptable psychometric properties. 
Conclusion: The use of the VISTAD as a screening tool at primary health care in people living 
with hypertension and/or diabetes is recommended. The VISTAD could therefore play a key 
role in the prevention and early treatment of individuals diagnosed with hypertension and/or 
diabetes across cultures and levels of education. The VISTAD needs to be validated in a large 
population representative of primary care patients diagnosed with hypertension and/or diabetes. 
 
Keywords: Screening; Visual Screening Tool; Depression; Anxiety; Hypertension; Diabetes 
  
BACKGROUND 
Current literature demonstrates that hypertension and diabetes have emerged as a major medical 
and public burden globally.1-4 South Africa is burdened with a high prevalence of hypertension 
and diabetes. There are 2.3 million people living with diabetes in South Africa,5 and 30% of the 
adult population is living with hypertension.6 Furthermore, hypertension and diabetes account 
for 17 million visits to health facilities in South Africa every year.1  
The diabetes and hypertension burden is further complicated by the increasingly high co-
morbidity with depression and anxiety disorders. Kumar and Clark7 argue that chronic diseases 
have psychological sequelae; however, these remain largely undetected and untreated at 
primary health care.8-10 Patients may be aware of their emotional state; however, they may be 
unable to describe accurately their subjective experience, according to Aitken.11 In addition, 
inadequate levels of mental health literacy, for both health care workers12 and patients, have 
been well established in research.13  
 
When clinicians do attempt to screen for mental disorders in patients with hypertension and/or 
diabetes, primary health care facilities are faced with barriers such as insufficient human and 
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material resources, lack of assessment instruments that can be appropriately applied to the 
diverse range of cultural and language groupings in South Africa and communication 
difficulties which lead to misunderstandings, misdiagnosis and/or inappropriate treatment. In 
addition to the above-mentioned barriers, pencil and paper tests are often not available or have 
to be read aloud to illiterate patients.14 Availability of simple, accurate and appropriate tools at 
primary health care could therefore contribute to the quality of detection and management of 
mental disorders, particularly in developing countries. Visual screening tools for depression 
and anxiety disorders could possibly circumvent the challenges posed by cultural, language, 
educational and time factors. This has been shown by Akena et al.15 who developed a simple 
visual screening tool for depression in patients living with HIV and AIDS in Uganda that can 
also be used by non specialists. However, the screening tool developed by Akena et al.15 does 
not screen for anxiety disorders. Screening for depression, according to Katon et al.,16 should 
also include anxiety disorders as these often coexist in patients living with chronic physical 
conditions. 
 
The use of pictures in aiding patients to describe emotions and thoughts has been well 
established in psychology. Psychological tests, referred to as projectives, such as the thematic 
apperception test (TAT),17 make use of drawings in order to allow access to unconscious 
thoughts, emotional life and internal dynamics – revealing hidden materials that clients are 
unable to disclose or unwilling to disclose. Ogle, Koen and Niehaus18 developed a visual 
screening tool for anxiety disorders and depression (VISTAD) using drawings based on the 
Hospital Anxiety and Depression Scale (HADS). The visual screening tool is referred to as the 
VISTAD. It includes depression items such as sleep disturbance, feeling miserable and sad, 
appetite and feeling life is not worth living, as well as anxiety items such as feeling frightened 
or having panic feelings for no reason, feeling frightened when going out of the house on my 
own, getting palpitations or sensations ‘butterflies’ in stomach or chest, irritable than usual and 
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worrying thoughts. The VISTAD, however, has not been validated for use in primary health 
care. 
 
The aim of the study was to validate the VISTAD as a screening tool for use in primary health 
care in individuals diagnosed with hypertension and/or diabetes and as a tool that can be used 





The study used a cross-sectional study design for validating the newly developed VISTAD.  
 
Setting 
The study was conducted in five primary health care centres in the Eastern Cape, South Africa. 
These primary health care centres provide health care services to two urban areas, 
KwaMagxaki, a predominantly black suburb, and Algoa Park, a mixed suburb, mixed race and 
white population, in Port Elizabeth; one peri-urban area in Uitenhage, predominantly black 
population; and two rural communities, KwaNonqubela, a black community, and Wentzel Park, 
a mixed race community in Alexandria, Eastern Cape.  
 
Sampling strategy 
Purposive sampling was utilised to recruit participants who were able to provide informed 
consent. Individuals were recruited while they were at the settings for their routine scheduled 
visit. Individuals between the ages of 18 and 60, diagnosed with diabetes and/or hypertension, 
were eligible for the study. Individuals known to have visual and hearing impairments, and 
intellectual disability were excluded from the study. 
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The principal researcher explained the purpose of the study and requested individuals who were 
interested in participating in the study to indicate their interest. Those who indicated an interest 
or wanted to get more information were interviewed in a private setting and provided with more 
details on the study.  
 
Data collection 
A demographic questionnaire was utilised to gather information about gender, age, race, 
marital status, level of education, employment status, family income and medical conditions. 
A short structured diagnostic interview, the MINI International Neuropsychiatric Interview 
version 5.0 (M.I.N.I),19 was used as a gold standard in the validation of the VISTAD. It covers 
17 Axis I disorders that include mood, anxiety, substance use, psychotic and eating disorders, 
and it also has a suicidality module and one Axis-II disorder, antisocial personality disorder.19 
The symptoms on the M.I.N.I are based on the Diagnostic and Statistical Manual of Mental 
Disorders. Sheehan et al.19 found the M.I.N.I to be a reliable and valid diagnostic tool, and it 
has been used in South African studies.20-23 The M.I.N.I has good psychometric properties; 
positive predictive values (PPV) are above 0.75 for depression, panic disorder, agoraphobia 
and post traumatic stress disorder.19 The PPV for generalized anxiety disorder agoraphobia 
are between 0.60-0.74 which is indicative of good values.19 Traditional screening tools such 
as the Centre for Epidemiological Surveys for Depression (CES-D),22 and the Kessler-10 (K-
10)23 have been validated against the M.I.N.I.24 The M.I.N.I has also been used as a gold 
standard in the validation of a visual screening tool for depression in people living with HIV 
in an environment with high illiteracy rates.15 There was a significant agreement between the 
visual screening tool for depression with receiver operating characteristic indicating an area 
under the curve of 0.82 for identifying depression. In a South African study, there was a 
significant agreement between the Kessler and depression (0.77) and anxiety disorders, 0.77 
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for post traumatic stress disorder, and 0.78 for generalized anxiety disorder (0.78).23 A study 
by Azevedo-Marques and Zuardi24 reported kappa coefficients ranging from 0.65 to 0.85, 
sensitivity was between 0.75 and 92, and specificity ranged from 0.90 to 0.99 for the M.I.N.I. 
Accuracy of the M.I.N.I ranged from 0.83 to 0.98. Taken together, the available data supports 
the notion that the M.I.N.I. provides reliable and valid diagnoses for mental disorders.  
 
The development of the VISTAD is discussed in detail in Ogle, Koen and Niehaus.18 In the 
VISTAD, a score of 1 is allocated when a participant endorses an abnormal state drawing and 
0 when none of the abnormal state symptoms are endorsed. The minimum score is 0 and the 
maximum score that could be obtained on the VISTAD is 10. A total score of 6 and above 
indicates a positive screen for depression and anxiety disorders on the VISTAD. 
 
Data analysis 
Descriptive statistics were used to describe demographic data. The M.I.N.I was used to 
categorise cases and non-cases of depression (major depressive episode) and anxiety disorders, 
that is, agoraphobia, generalised anxiety disorder (GAD), panic disorder, post-traumatic stress 
disorder (PTSD) and social phobia, excluding obsessive–compulsive disorder. The impact of 
education, employment and gender on the performance of VISTAD was investigated. 
Coefficient of correlation (coef.) indicated the correlation between the above-mentioned 
variables. The sensitivity and specificity and likelihood ratios (LR) were estimated. Sensitivity 
and specificity was calculated based on leave-one-out cross validation. Cut-off scores were 
informed by high specificity scores and moderate sensitivity scores. With a high specificity, the 
truly positives represent the mental disorder being screened for and not another condition, such 
as diabetes or hypertension. 
 
The plot of sensitivity versus specificity is referred to as the receiver operating characteristics 
91
Stellenbosch University  https://scholar.sun.ac.za
(ROC).25 The area under the curve (AUC) which is an effective measure of diagnostic test 
accuracy26 was used for interpretations of the data. An AUC value of 0.50–0.70 is considered 
low accuracy, 0.70–0.90 is considered moderate accuracy and 0.90 is considered high 
accuracy.26 Linear discriminant analysis was used to predict the disorder outcomes with the 
VISTAD drawing outcomes as predictors.  
 
Correspondence analysis was utilized to provide a two-dimensional graphical representation 
of the categorical data, the M.I.N.I. diagnoses and VISTAD items. This applies to categorical 
rather than continuous data.   All data analyses were done with STATA, version 14. 
 
Results 
Eighty-one participants from primary health care participated in the validation of the VISTAD. 
All the participants consented and participated in this study. However, out of the 81 participants, 
one declined to continue with completing the interview reporting that the VISTAD depicted his 
life, and it was painful to look at the images.  
 
In this study, we used demographic data of 79 participants as there was missing information 
from two participants. The majority of the participants were females, 69 (87%), with 10 (13%) 
males. Race distribution on the basis of gender showed that there were 43 black females, 15 
mixed ancestry females and 11 white females; and 7 black males, 2 white males and 1 mixed 
ancestry male. The mean age of the participants was 49, with standard deviation 8.6844 and 
minimum age 22 and maximum 60. Socio-demographic variables and related factors are set out 
in Table 1.  
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Table 1: Demographic and clinical characteristics of participants (N = 79). 
Variables n (%) 
Gender  
 Female 69(87) 
 Male 10(13) 
Language  
 Xhosa 48(61) 
 Afrikaans 29(37) 
 English 1 (1) 
 Shona 1 (1) 
Race  
 Black 50(63) 
 Mixed ancestry 16(20) 
 White 13(17) 
Education  
 No education 2 (3) 
 Primary level of education (Grades 1–6) 25(32) 
 Senior level of education (Grades 7–11) 33(42) 
 Matric (Grade 12) 15(19) 
 Post-matric qualification 4 (5) 
Employment  
 Yes 21(27) 
 No 58(73) 
Hypertension or diabetes  
 Hypertension only 47(59) 
 Diabetes only 1(1) 
 Hypertension and diabetes 31(39) 
Other medical conditions   
 Yes 43(54) 
 No 36(46) 






MINI diagnosis   
 Depression                       
 Panic disorder 
 Agoraphobia 
 Social phobia 
 Post-traumatic stress disorder 








Source: Authors’ own work 
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Accuracy of the visual screening tool for anxiety disorders and depression 
The AUC determined the accuracy of the VISTAD. The AUC in screening for depression is 
shown in Figure 1, PTSD in Figure 2, panic disorder in Figure 3, GAD in Figure 4, social phobia 
in Figure 5 and agoraphobia in Figure 6. The AUC score for depression shows a high accuracy 
of 0.91.  
 
Figures 1: Receiver operating curves of the visual screening tool for anxiety disorders and 
depression for depression. 
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The best cut-off scores were based on high specificity and moderate sensitivity. At a cut-off 
score of 6, the specificity was 90.91, and sensitivity was 72.00%, with 85% correctly classified 
cases. The specificity was 90.91 and sensitivity was 60.00%, with 81.25% correctly classified 
cases at a cut-off score of 7. 
 
Figure 2: Receiver operating curves of the visual screening tool for anxiety disorders and 
depression for post-traumatic stress disorder. 
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Figure 3: Receiver operating curves of the visual screening tool for anxiety disorders and 
depression for panic disorder. 
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Figure 4: Receiver operating curves of the visual screening tool for anxiety disorders and 
depression for generalised anxiety disorder. 
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Figure 5: Receiver operating curves of the visual screening tool for anxiety disorders and 
depression for social phobia. 























Stellenbosch University  https://scholar.sun.ac.za
 
Figure 6: Receiver operating curves of the visual screening tool for anxiety disorders and 
depression for agoraphobia. 
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The area under curve for PTSD was 0.87. At a cut-off point of 6 for PTSD, there were 68% 
correctly classified cases with a specificity of 72.22% and a sensitivity of 37%. Similar to 
PTSD, the area under curve for panic disorder was 0.87, which indicated moderate accuracy. 
The specificity of the VISTAD at a cut-off point of 6 was 81.25%, with a sensitivity of 43.75%.  
Agoraphobia had a specificity of 73.61%. Social phobia had a specificity of 72.22% at a cut-
off score of 6. Generalised anxiety disorder had a specificity of 74.63%, with 70% correctly 
classified cases.  
 
Response pattern  
In table 2, we analyzed the response patterns to the VISTAD. We compared participants with 
depression to those without depression, and participants with anxiety to those without anxiety. 
There was a statistically significant association between the diagnosis of depression, anxiety 
disorder and the majority of VISTAD items, excluding one.  There was no statistically 
significant association between all items and between the item, “feeling frightened when 
going out on my own” and a M.I.N.I diagnosis of major depression.  
 
Table 2: VISTAD Response Patterns  
VISTAD  Item  No Depression  Yes Depression Fisher Exact p  No Anxiety     Yes Anxiety Fisher Exact p 
Sleep disturbance           N=55 N=26       N=50  N=31 
 21 (38%)        24(92%)        p<0.01    8 (25%)             37 (76%)        p<0.01 
Feeling frightened for no reason 
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16 (29%)      15 (58%)   p=0.02  7 (22%)            24 (49%)         p=0.02 
Sad and miserable 
12 (22%) 20 (77%)        p<0.01     6 (19%) 26 (53%)         p<0.01 
Feeling frightened when going out on my own 
26 (47%) 16 (64%)           p=.22              10 (31%) 32 (67%)         p<0.01 
Palpitations 
18 (33%) 20 (80%)          p=00010    4 (13%)                  34(71%)        p<0.01 
Loss of appetite 
  8 (15%) 13 (52%)          p=00081  4 (13%)                   17 (35%)           p=0.04 
Life not worth living 
 3 (5%) 13 (52%)         p=.00001      2 (6%)                         14 (29%)           p=0.02 
Depressed 
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 9 (16%) 18 (72%)        p<0.01          5 (16%)                   22 (46%)        p<0.01 
Irritability  
9 (16%) 18  (72%)       p<0.01 9 (16%)                 18  (72%)      p<0.01 
Worrying thoughts constantly go through my mind 
 19 (35%) 19 (76%)       p=.00072 8 (25%)                   30 (63%)     p<0.01 
 
Correspondence analysis results 
Correspondence analysis was used to collapse the complex matrix of data (Figure 7). The 
spatially plotted data reduced the amount of information expressed in the response patterns of 
the participants (Table 2), while better expressing the associations present in the data.   
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Figure 7: VISTAD performance against M.I.N.I 
 
This plot illustrates some important aspects of the VISTAD’ performance in the study. Drawing 
2 (Feeling frightened for no reason) and 4 (Feeling frightened when going out on my own) 
relates spatially to the diagnosis of PTSD. On a conceptual level this spatial association makes 
clinical sense in terms of the symptoms of PTSD.  Drawing 5 (Palpitations or sensations in 
chest) related to panic disorder more closely and again makes sense in terms of the clinical 
features of this disorder. Drawing 8 (Depressed) related spatially most closely with a diagnosis 
of major depressive episode, while the rest of the items clustered between Major Depressive 
Episode and Panic Episode (MDE).  The exception is drawing 7 (Life is not worth living); if 
this item is not endorsed it is closely related to the absence of MDE, but endorsement of the 
item was not spatially closely related to the presence of MDE. There were 12 out of the 81 
participants who reported on the M.I.N.I. interview that they repeatedly consider hurting 
yourself, feel suicidal, or wish they were dead. 
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Demographic variables and the VISTAD items 
Fundamental to the validation of the VISTAD is the investigation of whether education levels, 
socio-economic status and gender have an impact on the performance of the VISTAD. Table 3 
presents the impact of level of education, gender and employment status on the performance of 
the VISTAD. There was a significant association between gender and performance on 
VISTAD, 0.042. 
 
Table 3: Impact of education, gender and employment status on the performance of the visual screening 
tool for anxiety disorders and depression. 
Variable Coef. SE t p > |t| 95% CI 
Level of education      
 Primary -0.7505694 3.557147 -0.21 0.833 -7.841612 to 6.340473 
 Senior -0.6239653 3.507459 -0.18 0.859 -7.615957 to 6.368026 
 Matric -2.326809 3.619307 -0.64 0.522 -9.541764 to 4.888147 
 Post-matric 0.0663401 4.089943 0.02 0.987 -8.086812 to 8.219493 
Gender      
 Male -3.715155 1.795807 -2.07 0.042 -7.295031 to -0.1352794 
Employment      
 Yes 0.4993359 1.26012 0.40 0.693 -2.012668 to 3.01134 
_cons 4.808826 3.425357 1.40 0.165 -2.019499 to 11.63715 
/sigma 4.344278 0.4488455   3.449521 to 5.239035 
Source: Authors’ own work 




In this study, we validated the VISTAD against the M.I.N.I. at primary health care in 
participants diagnosed with hypertension and/or diabetes. The VISTAD demonstrated high 
accuracy in detecting depression in participants with hypertension and/or diabetes. The AUC 
of the VISTAD was 0.91 in screening for depression. This is higher than the previously AUC 
of 0.82 established by the visual screening for depression established in people living with 
HIV/AIDS.15 At a cut-off score of 6, the VISTAD had satisfactory accuracy in classifying 
cases. This is similar to that of the HADS which the VISTAD is based on. At a cut-off score 
of 7, the HADS depression subscale provided the best balance between a sensitivity of 0.86 
and a specificity of 0.81 in cancer patients.26 In our study, the best balance was at a cut-off 
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score of 6 with a sensitivity of 0.72 and a specificity of 0.91, with 85% of the cases classified 
correctly. The AUC of VISTAD for both depression and anxiety is higher than that of the 
HADS. In study of 79 study patients with heart disease, Bambauer et al.27 reported AUC for 
HADS depression subscale of 0.81 and 0.70 for the HADS anxiety subscale against the 
M.I.N.I. The accuracy of the VISTAD is also similar to that of other widely used traditional 
screening tools such as the Patient Health Questionnaire (PHQ), with an AUC of 0.88 at a 
higher cut-off score in patients with type II diabetes and/or coronary heart disease in primary 
care,28 and the Kessler Scale (K10) for either anxiety or depression23 and CES-D, K-10 and 
PHQ-9 and with AUC ranging from 0.82 to 0.96 in people living with HIV.29 
The VISTAD had a higher AUC score compared to the recently validated WHO-5 for use in 
screening for depression in adults with diabetes. The AUC scores for WHO-5 in the validation 
study by Halliday et al.30 ranged between 0.85 and 0.88, which demonstrated that the WHO-5 
has moderate accuracy in screening for depression. This demonstrates that the VISTAD is a 
valuable tool for detecting depression. The optimal cut-off score chosen for depression was 6 
in this study. This is in line with the current practice of selecting higher cut-off scores to indicate 
the presence of depression.31 Similar to screening for depression, the optimal cut-off score 
chosen for anxiety disorders was 6.32 The AUC for anxiety disorders was in the moderate range. 
This indicates that the accuracy of the VISTAD was better for depression than for anxiety. This 
is consistent with findings made in the meta-analysis conducted by Vodemaier and Millman32 
on other screening tools. Previous research has also established a similar pattern. For example, 
GAD 7 showed lower sensitivity and specificity levels when compared to screening tools for 
depression.31 Makanjuola et al.33 also reported lower AUC values in Nigeria for K-6 and the 
General Health Questionnaire (GHQ-12). K-6 and GHQ-12 are sensitive and specific screening 
tools widely used and recommended for use in the screening for depression and/or depression 
in primary health care and community samples. The VISTAD demonstrated good performance 
105
Stellenbosch University  https://scholar.sun.ac.za
against the M.I.N.I, and its performance is consistent with widely used screening tools such as 
the HADS and PHQ-9. It provides valid screening of depression and anxiety. According to 
Kaufman and Charney,34 people living with depression also have a comorbid diagnosis of an 
anxiety disorder. We found that participants who endorsed symptoms of depression were also 
likely to endorse symptoms of anxiety on the VISTAD.   
 
Newly developed screening tools have also been recommended for use in patients with chronic 
medical conditions. A Ugandan study recommended the use of a visual screening tool for 
depression.15 This was based on its accuracy in detecting depression in people living with HIV. 
However, a study by Puertas et al.35 did not recommend the use of visual screening tools as it 
found the FACES test to have low accuracy. Akena et al.15 argues that screening tools, such as 
the FACES test, have often depended on a single facial picture depicting emotions ranging from 
a happy face to an extremely sad face. Participants with lower literacy levels struggle to 
comprehend the FACES screening tool according to Puertas et al.35 Previous research has 
established that education has an impact on people’s ability to comprehend and complete 
screening tools.36,37 Some, according to Snaith,38 are ashamed and pretend to answer questions 
and respond in a haphazard manner. This study demonstrated that education had no impact on 
the participants’ ability to comprehend and complete the VISTAD. The findings on the 
education and performance of the VISTAD are consistent with previous research by Akena et 
al.15 Furthermore, the socio-economic status had no impact on the participants’ ability to 
understand and complete the VISTAD. The majority of participants in this study were of low 
socio-economic status. We found that gender had a significant association with performance on 
the VISTAD. This is due to one VISTAD item, sleep disturbance item. The observed gender 
difference on the sleep disturbance item is consistent with previous research. Sleep related 
disorders such as insomnia are more common in women than men.39-41. Screening tools also 
have gender biases. Kerr and Kerr42 added that self-reporting screening tools for depression 
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have limitation with respect to gender, somatic symptoms and culture. 
 
Based on the M.I.N.I, we observed a depression prevalence of 32%. This is consistent with the 
findings of Jacob and Kostev’s study,43 which reported a prevalence of 33.7% in women and 
26.8% in men diagnosed with diabetes. Cols-Sagarra et al.44 reported a higher prevalence of 
43.4% in women with diabetes at primary health care. A prevalence of 31.4% was reported in 
a study conducted in rural and urban parts of the Eastern Cape, South Africa,45 and this finding 
is consistent with the prevalence observed in our study. 
 
Anxiety disorders such as panic disorder and PTSD had a high prevalence, with panic disorder 
at 40% and PTSD at 33%. Other studies have found a significantly higher prevalence of panic 
disorder in hypertensive patients.46 Also, in primary care, studies have observed a prevalence 
of PTSD ranging from 2.0% to 39.1% in hypertensive patients.47 Post-traumatic stress disorder, 
according to Seedat48 is among the most prevalent compared to other anxiety disorders in terms 
of lifetime and 12-month prevalence rates documented in epidemiological studies. The number 
of participants who had a positive diagnosis of a common mental disorder was high. This 
observation is consistent with previous research findings.49,50 Data on larger samples are needed 
to determine the prevalence of depression and anxiety disorders in primary care patients with 
hypertension and/or diabetes.  
 
STRENGHTS AND LIMITATIONS  
This is the first study to develop and validate a visual screening tool for both depression and 
anxiety disorders in primary health care participants diagnosed with hypertension and/or 
diabetes in South Africa. Furthermore, the use of the M.I.N.I in the study was not limited to the 
depression module, and the anxiety disorder module was also administered, except for 
obsessive–compulsive disorder module. The administration of the M.I.N.I depression module 
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only might artificially inflate the extent of the correlations as some participants with depression 
might have been better diagnosed with another disorder, such as anxiety disorder(s).15 Also, 
this could lead to a false accuracy of the visual screening tool. The strength of the study was 
enhanced by the inclusion of five different primary health care sites, which serve urban, peri-
urban and rural population.  
 
The validity of the VISTAD is based on the ten items used in its validation. In order to shorten 
the VISTAD, a process evaluation would need to be conducted to explore the experiences of 
using the VISTAD. This process will also determine how primary health care workers are using 
the VISTAD and whether a shorter tool would be effective and why. We would then need to 
devise criteria for performance for a shortened VISTAD. Futures studies will also be needed to 
determine this criteria degrades as items are removed.   
 
Because of the small size of the sample, we cannot generalise the findings of the study to all 
individuals attending primary health care. Thus, future research is needed to validate the 
VISTAD in a large primary health care population. Furthermore, the use of the VISTAD in 
primary health care with speech impairments and intellectual impairments needs further 
investigation. A further limitation is that this study was informed by the DSM-IV nosology. For 
example, PTSD is no longer described as an anxiety disorder in the current DSM-V, but as a 
trauma- and stressor-related disorder.  
 
CONCLUSIONS 
The visual screening tool is referred to as the VISTAD. The VISTAD is accurate in detecting 
depression and anxiety disorders in primary health care participants diagnosed with diabetes 
and/or hypertension. The use of the VISTAD is recommended as a screening tool for depression 
and anxiety disorders at primary care level in patients with hypertension and/or diabetes. 
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However, the VISTAD needs to be validated in a large population of primary care patients 
diagnosed with hypertension and/or diabetes.  
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The primary objective of this PhD was to develop and validate a simple and accurate visual 
screening tool for depression and anxiety disorders for adults attending primary health care 
centers with a diagnosis of hypertension and/or diabetes. The project was conceptualized 
against the realization as to the lack of availability of appropriate mental health screening tools 
that can be applied across language, education and resource barriers in a multi-cultural society 
such as South Africa. 
 
Thus we developed and validated the Visual Screening Tool for Anxiety Disorders and 
Depression (VISTAD). The VISTAD consists of ten culturally appropriate drawings depicting 
symptoms of depression and anxiety disorders. The study was borne from a need in the South 
African context where there is a lack of culturally appropriate and sensitive screening tools for 
common mental disorders that can be applied to diverse population groups and people with low 
and high levels of education.   
 
This study was divided into two phases. Phase one was the development of the VISTAD 
(chapter 2), and phase two (chapter 3 and 4) was the validation of the VISTAD. For the first 
phase of the study, we recruited adults attending primary health care, a maternal mental health 
clinic and from the general public. All the participants were asked to describe emotions and 
thoughts depicted in the drawings that represented symptoms of depression and anxiety 
disorders. Independent of culture, language, and level of education the participants 
demonstrated the ability to correctly identify and describe symptoms as associated with 
depression and anxiety disorders for ten of the thirteen proposed drawings. Our findings were 
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instrumental in identifying the drawings that were accurate enough to be included for the 
validation of the VISTAD in phase two of our study. 
 
In addition to the participants’ ability to describe the symptoms correctly, we also found that 
they referred to their lived experiences as they described emotions and thoughts depicted in the 
drawings. We concluded that these descriptions were connected to personal narratives of the 
participants and that the use of drawings offered an invaluable opportunity to explore emotional 
status across cultural and language boundaries. As participants narrated their life stories, they 
had a freedom of response where unconscious needs that they would ordinarily be unable or 
unwilling to report were expressed. The possible use of the VISTAD as a projective tool needs 
further exploration that falls beyond the scope of this study.  
 
For the second phase of the study, a sample of primary care patients with hypertension and/or 
diabetes were recruited. This sample was then used to validate the VISTAD. This sample is 
fully elucidated on in chapter three. Firstly, we described the presence of depression and anxiety 
disorders as determined using the Mini International Neuropsychiatric Interview (M.I.N.I.), 
quality of life (QOL) and patterns of alcohol and drug use. In our sample, panic disorder was 
the most common disorder at 40%, followed by post-traumatic stress disorder (PTSD) (33%), 
depression (32%) and generalised anxiety disorder (GAD) (17%). Social phobia (10%) and 
agoraphobia (10%) were the least prevalent anxiety disorders.  
 
The prevalence of depression in our study is consistent with findings from studies previously 
conducted in our study setting, Eastern Cape (Andersson et al., 2013). The Eastern Cape is a 
province where people are exposed to high levels of poverty and economic distress which has 
a negative impact on their health. This is consistent with our findings with the majority of 
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participants in our study unemployed and mostly reliant on state support, in the form of pensions 
and grants. 
 
International studies have reported a wide ranging prevalence of depression in people living 
with diabetes. These include 2%–84% (Naskar, Victor, & Nath, 2017), 32.7% (Calvin, Gaviria, 
& Rios, 2015) 33.7% in women and 26.8% in men (Jacob & Kostev, 2016) and 43.4% in women 
(Cols-Sagarra et al., 2016). Li, Li, Chen, Chen and Hu (2015) reported a prevalence of 26.8% 
of depression among patients with hypertension. We found a higher prevalence of depression 
in patients diagnosed with both hypertension and diabetes compared to patients diagnosed with 
hypertension only. The diagnosis of depression was associated with a poor QOL in our study. 
 
Generally, there is limited published literature on the prevalence of anxiety disorders in people 
living with hypertension and/or diabetes. From the data available, it is clear GAD is one of the 
highly prevalent but under-diagnosed anxiety disorders (Revicki et al., 2012). Whitworth et al. 
(2016) reported a prevalence of 6.5% for GAD, current, and a lifetime prevalence of 23%. Both 
these rates are higher than 17% found in our study.  
 
Agoraphobia and social phobia were less prevalent in our study. Both these having a prevalence 
of 10% which is consistent with previous research. According to the National Institute of 
Mental Health, 0.8% of American adults suffer from agoraphobia whilst Stein et al. (2009) 
reported a lifetime prevalence of agoraphobia of 9.8% in South Africa. In our study only 
patients diagnosed with hypertension had a diagnosis of agoraphobia with no association 
demonstrated between diabetes and agoraphobia.  
 
One of the costs associated with hypertension and diabetes is poor QOL. This was confirmed 
in our sample with participants demonstrating poor QOL in the physical health, psychological  
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and environmental domains. Based on this, we can conclude that our study participants were 
experiencing pain, low energy and fatigue and impairments in activities of daily living. They 
were also experiencing negative feelings, low self-esteem and poor concentration. We found a 
statistically significant association between diagnosis of depression, anxiety and poor QOL. 
Participants who had other medical conditions had a significantly poor QOL compared to 
participants without other medical conditions, and this shows that multimorbidity is associated 
with a poor QOL. 
 
An interesting finding from our study was that a significant number of participants did not 
engage in hazardous and harmful use of alcohol and drugs. Possibly, this finding could be 
related to primary health care staff focusing on early identification and appropriate intervention. 
However, we observed that participants who reported or endorsed irritability and suicidal 
ideation on the VISTAD were more likely to report drug related problems.  
 
The overarching goal of phase two was the validation of the VISTAD which was developed in 
phase one (chapter 4). The VISTAD showed it was highly accurate in detecting depression with 
an Area Under Curve (AUC) of 0.91 showing that the tool can be used to screen for depression 
in South African primary health care centers in adults living with hypertension and/or diabetes. 
Although the sample size was small, our findings are consistent with findings of studies with 
larger samples. We found the VISTAD to be valid in screening for depression with accuracy 
higher than that demonstrated in the validation of the Akena’s Visual Depression Inventory 
(AVIDI) (Akena et al., 2013)  and within the same range as that of other widely used screening 
tools, including the Patient Health Questionnaire (PHQ) in patients with Type II diabetes and/or 
coronary heart disease in primary care (van der Zwaan et al., 2016), the Kessler Psychological 
Distress Scale 10 (K10) for either anxiety or depression (Conway et al., 2016) and Center for 
Epidemiologic Studies Depression Scale (CES-D),  as well as K-10 and PHQ-9 in a group of 
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people diagnosed with HIV (Akena et al., 2013). The recently validated World Health 
Organization Wellbeing Index (WHO-5) for use in screening for depression in adults with 
diabetes had AUC ranging between 0.85–0.88. (Halliday et al., 2017) which is lower than the 
AUC 0.91 established in our study.  
We not only investigated the accuracy of the VISTAD in screening for depression, but also its 
accuracy in screening for anxiety disorders. Moderate accuracy was demonstrated with an AUC 
of 0.87 for panic disorder, 0.88 for agoraphobia, 0.85 for social phobia, 0.87 for PTSD and 0.83 
for GAD. Our findings are consistent with findings by Vodemaier and Millman (2011). 
Screening tools, including the Generalised Anxiety Disorder 7 (GAD 7), have acceptable 
sensitivity and specificity levels in screening for anxiety. However, as in our study these are 
lower when compared to screening tools for depression (Conway et al., 2016). Makanjuola et 
al. (2014) also reported lower AUC in Nigeria for Kessler Psychological Distress Scale 6 (K-
6) and General Health Questionnaire 12 (GHQ-12).  
 
Our findings showed that the VISTAD has high accuracy in detecting depression and moderate 
accuracy in detecting anxiety disorders in adults attending primary health care centers with a 
diagnosis of hypertension and/or diabetes. 
 
Our aim was not to elucidate the pathways between hypertension and/or diabetes and depression 
and anxiety disorders but rather to describe the presence thereof and determine the VISTAD’s 
accuracy in positively identifying these illnesses. The high number of participants diagnosed 
with depression and anxiety disorders in primary health care adults living with hypertension 
and/or diabetes does not imply causality. Rather, it highlights the importance of detecting and 
treating depression and anxiety disorders in these patients. The high prevalence of these 
disorders presented in this study highlights the urgent need for preventative action to minimize 
suffering and costs to society. The data should be of particular interest to governing structures, 
121
Stellenbosch University  https://scholar.sun.ac.za
clinicians and researchers as available information is in many cases limited and outdated 
information (Tomlinson et al., 2009). Our study results could contribute to processes with 
regards to planning and allocation of resources, particularly for mental health care at a primary 
health care level. Conway et al. (2016) argued that the generalizability of their findings were 
supported as they were consistent with previous research. Similarly our findings on the 
prevalence of depression and anxiety disorders are consistent with the available literature. 
However, they should be interpreted with caution as our study sample was small. We believe 
that the VISTAD represents an important contribution towards furthering the integration of the 
management of mental health conditions into the primary health care system. 
 
Firstly, it addresses the challenges posed by cultural, language, educational and time factors 
when attempting to screen for common mental disorders. Secondly, the VISTAD includes 
symptoms of depression and anxiety disorders in one screening tool. Katon, Lin, and Kroenke 
(2007) have argued that the assessment of depressive disorders should include anxiety disorders 
since these disorders often co-exist in chronic physical conditions. 
 
It is well known and widely reported in the literature that primary health care access to mental 
health specialists is severely limited. Thus, the true integration of mental health care into 
primary health will improve the early identification and management of depression and anxiety 
disorders in people living with chronic illnesses. The availability of simple to use and culturally 
appropriate tools such as the VISTAD brings this goal much closer to becoming a reality. 
 
Conclusions and reflective assessment of contribution 
In conclusion, we report on the successful development of the VISTAD. To the best of our 
knowledge, this is the first study to develop and validate a visual screening tool, for both 
depression and anxiety disorders in primary health care patients with hypertension and/or 
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diabetes in a developing world setting. The VISTAD is self-administered and any primary 
health care worker can easily be trained to score it. We demonstrated that it can be administered 
to patients irrespective of level of education, language and cultural background. The findings 
from the developmental phase of the VISTAD provide an opportunity for further exploration 
of the VISTAD as a projective tool as it supported that drawings can be used to describe 
emotions and thoughts associated with depression and anxiety disorders.  
 
We found a high prevalence of depression and anxiety disorders in adults diagnosed with 
hypertension and/or diabetes in our study when compared to other studies. Socioeconomic 
factors are a contributor to this high prevalence and this emphasizes the importance of having 
a health care system providing care that is beneficial to all. With simple to use and culturally 
appropriate tools such as the VISTAD, the detection of depression and anxiety disorders could 
be improved. This study highlights the urgency for the integration of health care services in 
order to address the impact of depression, and anxiety disorders coexisting with chronic 
illnesses such as diabetes and/or hypertension. This study showed that hypertension and 
diabetes can compromise the QOL of patients, if left undetected.  
 
In order to pursue a more comprehensive role-out of the VISTAD, it needs to be validated in a 
larger sample. Furthermore, the VISTAD only assesses the likelihood of the presence of 
depression and anxiety disorders symptoms and not severity in categories such as mild, 
moderate and severe. A follow-up study is recommended to explore the symptomatology of 
depression and anxiety disorders in people living with hypertension and/or diabetes in order to 
investigate the particular burden and management of these illnesses. The use of the VISTAD 
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Ethics Reference #: S14/11/262
Title: The development of a visual screening sale for depression and anxiety in patients with hypertention and/or diabetes.
Dear Miss Zimbini Ogle,
The New Application received on 14-Nov-2014, was reviewed by Health Research Ethics Committee 1 via Committee Review procedures on
04-Feb-2015 and has been approved.
Please note the following information about your approved research protocol:














Please remember to use your protocol number (S14/11/262) on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review:
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the Committee before the year has expired.
The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Translation of the consent document to the language applicable to the study participants should be submitted.
Federal Wide Assurance Number: 00001372
Institutional Review Board (IRB) Number: IRB0005239
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States
Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes
2004 (Department of Health).
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant authorities (Western Cape
Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel:
130
Stellenbosch University  https://scholar.sun.ac.za
+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and documents please visit: www.sun.ac.za/rds
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Investigator Responsibilities
Protection of Human Research Participants
Some of the responsibilities investigators have when conducting research involving human participants are listed below:
1.Conducting the Research. You are responsible for making sure that the research is conducted according to the HREC approved research protocol. You
are also responsible for the actions of all your co-investigators and research staff involved with this research.
2.Participant Enrolment. You may not recruit or enrol participants prior to the HREC approval date or after the expiration date of HREC approval. All
recruitment materials for any form of media must be approved by the HREC prior to their use. If you need to recruit more participants than was noted
in your HREC approval letter, you must submit an amendment requesting an increase in the number of participants.
3.Informed Consent. You are responsible for obtaining and documenting effective informed consent using only the HREC-approved consent documents,
and for ensuring that no human participants are involved in research prior to obtaining their informed consent. Please give all participants copies of the
signed informed consent documents. Keep the originals in your secured research files for at least fifteen (15) years.
4.Continuing Review. The HREC must review and approve all HREC-approved research protocols at intervals appropriate to the degree of risk but not
less than once per year. There is no grace period. Prior to the date on which the HREC approval of the research expires, it is your responsibility to
submit the continuing review report in a timely fashion to ensure a lapse in HREC approval does not occur. If HREC approval of your research
lapses, you must stop new participant enrolment, and contact the HREC office immediately.
5.Amendments and Changes. If you wish to amend or change any aspect of your research (such as research design, interventions or procedures, number
of participants, participant population, informed consent document, instruments, surveys or recruiting material), you must submit the amendment to the
HREC for review using the current Amendment Form. You may not initiate any amendments or changes to your research without first obtaining
written HREC review and approval. The only exception is when it is necessary to eliminate apparent immediate hazards to participants and the HREC
should be immediately informed of this necessity.
6.Adverse or Unanticipated Events. Any serious adverse events, participant complaints, and all unanticipated problems that involve risks to participants
or others, as well as any research-related injuries, occurring at this institution or at other performance sites must be reported to the HREC within five (5)
days of discovery of the incident. You must also report any instances of serious or continuing problems, or non-compliance with the HRECs
requirements for protecting human research participants. The only exception to this policy is that the death of a research participant must be reported in
accordance with the Stellenbosch Universtiy Health Research Ethics Committee Standard Operating Procedures www.sun025.sun.ac.za/portal
/page/portal/Health_Sciences/English/Centres%20and%20Institutions/Research_Development_Support/Ethics/Application_package All reportable
events should be submitted to the HREC using the Serious Adverse Event Report Form.
7.Research Record Keeping. You must keep the following research-related records, at a minimum, in a secure location for a minimum of fifteen years: the
HREC approved research protocol and all amendments; all informed consent documents; recruiting materials; continuing review reports; adverse or
unanticipated events; and all correspondence from the HREC
8.Reports to the MCC and Sponsor. When you submit the required annual report to the MCC or you submit required reports to your sponsor, you
must provide a copy of that report to the HREC. You may submit the report at the time of continuing HREC review.
9.Provision of Emergency Medical Care. When a physician provides emergency medical care to a participant without prior HREC review and approval,
to the extent permitted by law, such activities will not be recognised as research nor will the data obtained by any such activities should it be used in
support of research.
10.Final reports. When you have completed (no further participant enrolment, interactions, interventions or data analysis) or stopped work on your
research, you must submit a Final Report to the HREC.
11.On-Site Evaluations, MCC Inspections, or Audits. If you are notified that your research will be reviewed or audited by the MCC, the sponsor, any
other external agency or any internal group, you must inform the HREC immediately of the impending audit/evaluation.
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